Topical interventions for genital lichen sclerosus (Review)

Chi CC, Kirschig G, Baldo M, Brackenbury F, Lewis F, Wojnarowska F

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2011, Issue 12

http://www.thecochranelibrary.com
# Table of Contents

1. **Header**

2. **Abstract**

3. **Plain Language Summary**

4. **Background**

5. **Objectives**

6. **Methods**

7. **Results**
   - Figure 1
   - Figure 2

8. **Discussion**

9. **Authors' Conclusions**

10. **Acknowledgements**

11. **References**

12. **Characteristics of Studies**

13. **Data and Analyses**
   - Analysis 1.1. Comparison 1 Clobetasol vs placebo, Outcome 1 Participant-rated improvement or remission of symptoms.
   - Analysis 1.2. Comparison 1 Clobetasol vs placebo, Outcome 2 Investigator-rated global degree of improvement.
   - Analysis 2.1. Comparison 2 Mometasone vs placebo, Outcome 1 Investigator-rated change in clinical score of phimosis from baseline.
   - Analysis 3.1. Comparison 3 Testosterone vs placebo, Outcome 1 Participant-rated improvement or remission of symptoms.
   - Analysis 3.2. Comparison 3 Testosterone vs placebo, Outcome 2 Investigator-rated improvement of gross appearance.
   - Analysis 3.3. Comparison 3 Testosterone vs placebo, Outcome 3 Adverse drug reactions that were severe enough to require withdrawal of treatment.
   - Analysis 4.1. Comparison 4 Dihydrotestosterone vs placebo, Outcome 1 Investigator-rated gross improvement.
   - Analysis 5.1. Comparison 5 Testosterone vs clobetasol, Outcome 1 Participant-rated improvement or remission of symptoms.
   - Analysis 5.2. Comparison 5 Testosterone vs clobetasol, Outcome 2 Investigator-rated global degree of improvement.
   - Analysis 5.3. Comparison 5 Testosterone vs clobetasol, Outcome 3 Adverse drug reactions that were severe enough to require withdrawal of treatment.
   - Analysis 5.4. Comparison 5 Testosterone vs clobetasol, Outcome 4 Adverse drug reactions that were not severe enough to require cessation of treatment.
   - Analysis 6.1. Comparison 6 Testosterone vs dihydrotestosterone, Outcome 1 Participant-rated remission of itching.
   - Analysis 6.2. Comparison 6 Testosterone vs dihydrotestosterone, Outcome 2 Investigator-rated gross improvement.
   - Analysis 7.3. Comparison 7 Testosterone vs placebo as maintenance therapy, Outcome 3 Adverse drug reactions that were severe enough to require cessation of treatment.
   - Analysis 8.1. Comparison 8 Progesterone vs placebo, Outcome 1 Participant-rated improvement or remission of symptoms.
   - Analysis 8.2. Comparison 8 Progesterone vs placebo, Outcome 2 Investigator-rated global degree of improvement.
   - Analysis 9.1. Comparison 9 Pimecrolimus vs clobetasol, Outcome 1 Change in pruritus (VAS-PR).
   - Analysis 9.2. Comparison 9 Pimecrolimus vs clobetasol, Outcome 2 Change in burning/pain (VAS-BP).
   - Analysis 9.3. Comparison 9 Pimecrolimus vs clobetasol, Outcome 3 Investigator-rated global degree of improvement.

14. **Additional Tables**

15. **Appendices**

16. **History**

17. **Contributions of Authors**

18. **Declarations of Interest**

19. **Sources of Support**

20. **Differences Between Protocol and Review**
Topical interventions for genital lichen sclerosus

Ching-Chi Chi¹, Gudula Kirtschig², Maha Baldo³, Fabia Brackenbury⁴, Fiona Lewis⁵, ⁶, Fenella Wojnarowska³

¹Department of Dermatology and Centre for Evidence-Based Medicine, Chang Gung Memorial Hospital-Chiayi, Chang Gung University College of Medicine, Chiayi, Taiwan. ²Department of Dermatology, VU University Medical Center, Amsterdam, Netherlands. ³Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK. ⁴c/o Cochrane Skin Group, University of Nottingham, Nottingham, UK. ⁵Department of Dermatology, Wexham Park Hospital, Heatherwood & Wexham Park NHS Foundation Trust, Slough, UK. ⁶St John’s Institute of Dermatology, St Thomas’ Hospital, London, UK

Contact address: Ching-Chi Chi, Department of Dermatology and Centre for Evidence-Based Medicine, Chang Gung Memorial Hospital-Chiayi, Chang Gung University College of Medicine, 6, Sec West, Chia-Pu Road, Puzih, Chiayi, 61363, Taiwan. chingchi@cgmh.org.tw.

Editorial group: Cochrane Skin Group.
Review content assessed as up-to-date: 16 September 2010.


Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Abstract

Background

Lichen sclerosus is a chronic, inflammatory skin condition that most commonly occurs in adult women, although it may also be seen in men and children. It primarily affects the genital area and around the anus, where it causes persistent itching and soreness. Scarring after inflammation may lead to severe damage by fusion of the vulval lips (labia); narrowing of the vaginal opening; and burying of the clitoris in women and girls, as well as tightening of the foreskin in men and boys, if treatments are not started early. Affected people have an increased risk of genital cancers.

Objectives

To assess the effects of topical interventions for genital lichen sclerosus and adverse effects reported in included trials.

Search methods

We searched the following databases up to 16 September 2011: the Cochrane Skin Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE (from 2005), EMBASE (from 2007), LILACS (from 1982), CINAHL (from 1981), British Nursing Index and Archive (from 1985), Science Citation Index Expanded (from 1945), BIOSIS Previews (from 1926), Conference Papers Index (from 1982), and Conference Proceedings Citation Index - Science (from 1990). We also searched ongoing trial registries and scanned the bibliographies of included studies, published reviews, and papers that had cited the included studies.

Selection criteria

Randomised controlled trials (RCTs) of topical interventions in genital lichen sclerosus.

Data collection and analysis

Two authors independently selected trials, extracted data, and assessed the risk of bias. A third author was available for resolving differences of opinion.
Main results

We included 7 RCTs, with a total of 249 participants, covering 6 treatments. Six of these RCTs tested the efficacy of one active intervention against placebo or another active intervention, while the other trial tested three active interventions against placebo.

When compared to placebo in one trial, clobetasol propionate 0.05% was effective in treating genital lichen sclerosus in relation to the following outcomes: ‘participant-rated improvement or remission of symptoms’ (risk ratio (RR) 2.85, 95% confidence interval (CI) 1.45 to 5.61) and ‘investigator-rated global degree of improvement’ (standardised mean difference (SMD) 5.74, 95% CI 4.26 to 7.23).

When mometasone furoate 0.05% was compared to placebo in another trial, there was a significant improvement in the ‘investigator-rated change in clinical grade of phimosis’ (SMD -1.04, 95% CI -1.77 to -0.31).

Both trials found no significant differences in reported adverse drug reactions between the corticosteroid and placebo groups.

The data from four trials found no significant benefit for topical testosterone, dihydrotestosterone, and progesterone. When used as maintenance therapy after an initial treatment with topical clobetasol propionate in another trial, topical testosterone worsened the symptoms (P < 0.05), but the placebo did not.

One trial found no differences between pimecrolimus and clobetasol propionate in relieving symptoms through change in pruritus (itching) (SMD -0.33, 95% CI -0.99 to 0.33) and burning/pain (SMD 0.03, 95% CI -0.62 to 0.69). However, pimecrolimus was less effective than clobetasol propionate with regard to the ‘investigator-rated global degree of improvement’ (SMD -1.64, 95% CI -2.40 to -0.87). This trial found no significant differences in reported adverse drug reactions between the pimecrolimus and placebo groups.

Authors’ conclusions

The current limited evidence demonstrates the efficacy of clobetasol propionate, mometasone furoate, and pimecrolimus in treating genital lichen sclerosus. Further RCTs are needed to determine the optimal potency and regimen of topical corticosteroids, examine other topical interventions, assess the duration of remission or prevention of flares, evaluate the reduction in the risk of genital squamous cell carcinoma or genital intraepithelial neoplasia, and examine the efficacy in improving the quality of the sex lives of people with this condition.

PLAIN LANGUAGE SUMMARY

Topical treatments for genital lichen sclerosus

Lichen sclerosus is a chronic skin disease that mostly affects adult women, but also men and children. It mainly occurs in the genital area and around the anus. Affected women and girls frequently report itching, pain, and burning in the involved area. Scarring after inflammation may cause fusion of the vaginal lips, narrowing of the vaginal opening, and burying of the clitoris. Sex is often painful, less pleasurable, or impossible because of the pain. Lichen sclerosus in men and boys may cause tightening of the foreskin, leading to difficulty in passing urine or painful erection. Pain on opening the bowels may also be present, causing constipation, especially in children. Treating this disease is beneficial as the symptoms can be relieved, and further damage to the genital area and around the anus may be prevented. Various topical treatments for lichen sclerosus have been devised. This review aimed to identify which topical treatments are effective and safe.

We included 7 trials, with a total of 249 participants, covering 6 treatments in this review. Topical clobetasol propionate and mometasone furoate were effective in treating genital lichen sclerosus. There was no substantial difference in the efficacy of relieving symptoms (e.g. itching and pain) between pimecrolimus cream and clobetasol propionate, but the former was less effective in improving gross appearance.

More research is needed for a number of reasons: to decide the strength of steroids that should be used, as well as the frequency and length of application to the skin which gives the best results; to examine other skin treatments; to assess the long-term benefits of topical treatments with regard to relieving symptoms and reducing the risk of developing genital cancers; and to examine the benefits of treatments on the quality of the sex lives of people with this condition.
BACKGROUND

Definition

Lichen sclerosus is a chronic inflammatory skin condition which causes distressing symptoms and discomfort. It most frequently occurs in women (Brownstein 1973), but also in men and children. Lichen sclerosus may affect any site, but it occurs mainly in the anogenital area (the genital area and around the anus), where it causes itching and pain. Scarring leading to the destruction of the anogenital structures, such as fusion of the vulval lips (labia), narrowing of the vaginal opening, and burying of the clitoris in women and girls, as well as tightening of the foreskin in men and boys, is common (Powell 1999).

Description of the condition

The primary lesions are flat, ivory-coloured spots, which may merge together into crinkly thin patches. Purpura or ecchymosis (bruising) is common. The Koebner phenomenon (the development of lesions in previously normal skin that has been scratched or damaged) occurs in lichen sclerosus (Wallace 1971). In women and girls, scarring after inflammation may cause fusion of the labia minora (lips), narrowing of the vaginal introitus (vaginal opening), and burying of the clitoris. They commonly report itching, pain, burning, painful or less pleasurable sexual intercourse, and anal or genital bleeding. Constipation causing painful defecation may also be a problem, especially in children. Lichen sclerosus in men and boys usually occurs on the glans penis and/or foreskin, and it may cause phimosis (narrowing of the opening of the foreskin) in a previously retractable foreskin or adhesions of the foreskin to the glans causing painful erection. Meatal stenosis (narrowing of the urethral opening) may lead to problems passing urine and urinary obstruction. Lichen sclerosus away from the genital area alone has been reported in about 6% of all affected women (Wallace 1971). Lichen sclerosus of the mouth is very unusual and is usually asymptomatic (Meffert 1995; Tremaine 1989).

The diagnosis in most affected people is made clinically, but a confirmatory biopsy is helpful if there is clinical doubt about the diagnosis. It also helps to detect any atypical or malignant changes. A vulval biopsy is not usually performed in children, except in cases that fail to respond to treatments (Neill 2010).

Epidemiology

Lichen sclerosus can occur at any age, but it has two main peaks in incidence: The first occurs before puberty for both girls and boys, and the second peaks are, for women, after the menopause, and, for men, between 30 and 50 years of age. The prevalence is estimated to be between 1:30 and 1:1000 in adults (Leibovitz 2000; Tasker 2003). Women are more commonly affected than men, with the female/male (F/M) ratio varying from 6:1 to 10:1 (Brownstein 1973; Wallace 1971). However, the F/M ratio appears to be the reverse of this in childhood (Kyriakis 2007), as the estimated prevalence is 1:900 in girls aged between 2 and 16 years (Powell 2001) and 1:200 in boys aged 0 to 14 years (Shankar 1999). One explanation for those, seemingly, reverse figures may be that boys with phimosis are seen earlier in life by a physician than girls, who might have little or no subjective symptoms of early lichen sclerosus. Many of the boys with a tightened foreskin will be circumcised and may, therefore, not have active lichen sclerosus in adulthood; whereas, symptoms will increase in women. Lichen sclerosus seems more common in Caucasians, but there are reports in other ethnic groups (Tasker 2003). Extrapolation from the Oxford clinic data suggests that approximately 150 to 200 women per million population present to a clinician each year (Clayton 2006).

Pathogenesis

The cause of lichen sclerosus is unknown, but there is a strong association with autoimmune diseases. Between 21.5% and 34% of those with lichen sclerosus have an associated autoimmune disease: Thyroid disease, alopecia areata, vitiligo, and pernicious anaemia are the most commonly seen (Meyrick 1988). These associations are more common in women and girls (28% to 54%) (Cooper 2008; Marren 1995) than in men and boys (3%) (Azuredia 1999); furthermore, up to 74% of those affected were found to have circulating autoantibodies (Harrington 1981). Recent studies show an increased incidence of autoantibodies to the extracellular matrix protein 1 in lichen sclerosus, which supports the idea of lichen sclerosus being a (humoral) autoimmune disease (Oyama 2003). In addition, there is evidence of both autoantibody and T-cell reactivity to basement membrane proteins (Baldo 2010; Howard 2004). The high incidence of lichen sclerosus in postmenopausal women suggests a pathogenic role of reduced oestrogen levels; however, a protective effect from oestrogens, e.g. that women before menopause will not develop lichen sclerosus, has not been observed (Powell 1999; Tasker 2003). Genetic factors are implicated, and cases of familial lichen sclerosus have been reported (Sherman 2010). Immunogenetic studies have demonstrated a significant association with the histocompatibility antigens, HLA class II antigen DRQ7 and DRBI*12 (Gao 2005; Marren 1995). An infective aetiology has been postulated, but there are no clear data to show that lichen sclerosus is related to an infectious organism (Funaro 2004).

Impact

Lichen sclerosus has a huge impact on a person's quality of life by interfering with function (particularly sexual functioning) and self image, and the resultant distress and anxiety are immediately
apparent. Many affected people feel embarrassed; some have persistent itching and pain (despite successful control of the inflammation), and many are concerned about how the disorder may progress. The lifetime risk of the development of vulval squamous cell carcinoma (SCC) in women with lichen sclerosus is 4% to 5% (Powell 1999; Wallace 1971), whilst the background lifetime risk of vulval SCC in the UK population is 0.3% (CRUK 2010). Also, vulval verrucous carcinoma has been associated with lichen sclerosus (Wang 2010). The mechanism of development of genital malignancies in lichen sclerosus is unclear, but they may involve oncogenic human papillomavirus infection, altered expression of p53 oncogene, chronic inflammation of lichen sclerosus, and oxidative stress (Wang 2010).

Description of the intervention

There is no cure for lichen sclerosus; however, there are good outcomes as a result of treating the disease. These include the relief of subjective symptoms (itching, pain) and prevention of further anatomical changes (due to sclerosis and fusion). Some clinical signs may be reversed, but any scarring that has occurred will remain (Cooper 2004; Renaud-Vilmer 2004). It is possible that treatment may prevent malignant transformation, but this needs to be evaluated.

At present, potent or very potent topical corticosteroids are generally considered the intervention of choice (e.g. clobetasol propionate 0.05% cream or ointment) when treating lichen sclerosus (Cooper 2004; Dalziel 1991; Dalziel 1993; Funaro 2004). The Guidelines for the management of lichen sclerosus, prepared for dermatologists on behalf of the British Association of Dermatologists, recommend the use of a very potent corticosteroid ointment or cream (Neill 2010), which is also effective in treating lichen sclerosus in children (Fischer 1997; Powell 1999). Intralesional injection of corticosteroids has been shown to be effective and may be an alternative to topical corticosteroids when treating thick, resistant plaques of lichen sclerosus (Mazdisnian 1999). However, the adverse effects of corticosteroid-induced skin atrophy (skin thinning) and telangiectasia (distended blood capillaries giving a spidery red spot) have to be considered. Whether corticosteroid-induced immunosuppression increases the risk of vulval malignancy also needs evaluation.

Low serum levels of dihydrotestosterone, free testosterone, and androstenedione were found in women with untreated vulval lichen sclerosus (Friedrich 1984). Based on a hormone-deficient theory of lichen sclerosus, topical hormones (e.g. androgens) have been used widely in the past in women with lichen sclerosus. A few studies found topical testosterone propionate effective in treating vulval lichen sclerosus (Friedrich 1971; Skierlo 1987). However, androgen-associated side-effects are common, for example, hirsutism and clitoral hypertrophy (Bornstein 1998). A study reported topical retinoids are effective, but skin irritation may limit their use (Virgili 1995). Topical immunomodulators have pharmacological effects similar to topical corticosteroids, but they do not have the side-effects of skin atrophy and telangiectasia (Henge 2006). A pilot study of topical ciclosporin did not find beneficial effect in genital lichen sclerosus (Carli 1992). Other topical immunomodulators, e.g. tacrolimus and pimecrolimus, have better skin penetration than topical ciclosporin and seem more promising in treating genital lichen sclerosus (Boms 2004; Henge 2006). However, a burning sensation may be experienced with their use, and the long-term safety profile of these newer immunomodulators needs to be evaluated.

Photodynamic therapy employs light irradiation of the skin pre-treated with a photosensitiser, such as 5-aminolevulinic acid, and generates highly reactive oxidants (e.g. superoxide or hydroxyl radicals). The photodynamic effect might cause a light-induced cytotoxic effect (Hillemanns 1999). Irradiation of a photosensitiser, poralox applied to the skin by ultraviolet A known as PUV A (Psoralen-ultraviolet A), may have clinical efficacy in treating skin conditions through an immunomodulatory mechanism or via an inhibitory effect on DNA synthesis. In addition, UVA irradiation induces collagenase expression and activity in the skin, possibly through generation of singlet oxygen (Reichrath 2002). Anecdotal reports have found photodynamic therapy and topical PUV A effective for treating genital lichen sclerosus (Hillemanns 1999; Reichrath 2002); however, the potential increased risk of skin cancers associated with PUV A may limit its use (Patel 2009). Emollients increase the water content of the skin and improve the skin barrier function, protecting it from attack by noxious substances (Loden 1999). Daily use of emollients accelerates normalization of the damaged skin (Held 2001) and is effective in improving mild subclinical inflammation in experiments (Kikuchi 2003). Therefore, emollients have been used as a maintenance therapy for vulval lichen sclerosus (Simonart 2008).

Why it is important to do this review

Although there is some evidence to support the use of the topical interventions for lichen sclerosus listed below (under Types of interventions), as there had been no systematic review of the literature, we conducted this Cochrane systematic review to find out if the currently recommended treatment regimens are based on evidence. Our aim with this review was to determine the appropriate interventions, possible risks, and side-effects, as well as assess the level and quality of the currently available evidence, in order to identify areas of uncertainty or gaps in knowledge that require further research.

OBJECTIVES

To assess the efficacy of topical interventions for genital lichen sclerosus and adverse effects reported in included trials.
METHODS

Criteria for considering studies for this review

Types of studies
We included randomised controlled trials (RCTs) to evaluate the efficacy of topical interventions for genital lichen sclerosus. Cross-over trials and within-patient studies were also included.

Types of participants
We included anyone who had been diagnosed with genital lichen sclerosus by a medical practitioner. The diagnosis of lichen sclerosus was ideally made upon clinical and histological criteria; however, we also accepted clinical diagnosis alone if the diagnosis of lichen sclerosus was made by an experienced investigator (dermatologist, urologist, or gynaecologist).

Types of interventions
We searched for RCTs on the following topical interventions:
- topical corticosteroids (potency defined by the British National Formulary (BNF 2010)) (see Table 1);
- topical androgens;
- topical oestrogen;
- topical progesterone;
- topical retinoids;
- topical immunomodulators (tacrolimus, pimecrolimus, ciclosporin);
- topical oxatomide;
- photodynamic therapy;
- topical PUVA therapy;
- cryotherapy;
- emollients;
- ultrasound; and
- other topical interventions.

Types of outcome measures

Primary outcomes
1) Participant-rated improvement or remission of symptoms (in terms of quality of life, pain, itching, and less pain with intercourse).
2) Investigator-rated global degree of improvement (in terms of pallor, purpura, hyperkeratosis, ulceration, erosion, erythema, sclerosis, and scarring).

When we assessed these primary outcomes, we set a time point of measurement at three to six months into therapy.
3) Adverse drug reactions severe enough to require withdrawal of treatment, including severe skin irritation or infection.

Secondary outcomes
1) Adverse drug reactions that were not severe enough to require cessation of treatment, such as mild skin irritation, atrophy, or telangiectasia.
2) Duration of remission or prevention of subsequent flares, or both.
3) Development of genital squamous cell carcinoma (SCC) or genital intraepithelial neoplasia.

Search methods for identification of studies
We aimed to identify all relevant randomised controlled trials (RCTs) regardless of language or publication status (published, unpublished, in press, or in progress).

Electronic searches
We searched the following databases up to 16 September 2011:
- the Cochrane Skin Group Specialised Register using the following search terms: (lichen and (sclerosus or atrophy* or albus or sclereux or sclero-atrophy* or vulva*)) or (kraurosis and (vulva* or penis)) or (balanitis and (xerotica or obliteran* or sclerotica)) or (vulva* and dystroph*) or (white and spot and disease*);
- the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library using the search strategy in Appendix 1;
- MEDLINE (from 2005) using the search strategy in Appendix 2;
- EMBASE (from 2007) using the search strategy in Appendix 3;
- LILACS (Latin American and Caribbean Health Science Information database, from 1982) using the search strategy in Appendix 4;
- CINAHL (Cumulative Index to Nursing and Allied Health Literature, from 1981) using the search strategy in Appendix 5; and
- SCI-EXPANDED (Science Citation Index Expanded, from 1945) using the search strategy in Appendix 7.

The UK and US Cochrane Centres (CCs) have an ongoing project to systematically search MEDLINE and EMBASE for reports of trials, which are then included in the Cochrane Central Register of Controlled Trials. Searching has currently been completed in MEDLINE to 2004 and in EMBASE to 2006. Further searching has been undertaken for this review by the Cochrane Skin Group to cover the years that have not been searched by the UK and US CCs.

A final prepublication search for this review was undertaken on 16 September 2011. No further completed studies were identified, but two relevant ongoing RCTs were found and added to the
references. They will be incorporated into the next update of the review.

Ongoing Trials Registers
On 20 September 2011 we searched for reports of trials in the following ongoing trials databases using the search strategy in Appendix 8:
- The metaRegister of controlled trials (www.controlled-trials.com).
- The US National Institutes of Health ongoing trials register (www.clinicaltrials.gov).
- The World Health Organization International Clinical Trials Registry platform (www.who.int/trialsearch).
- The Australian New Zealand Clinical Trials Registry (www.anzctr.org.au).
- The Ongoing Skin Trials Register (www.nottingham.ac.uk/ongoingskintrials).

Searching other resources

Grey literature
On 16 September 2011 we searched BIOSIS Previews (from 1926) for relevant studies using the search strategy in Appendix 7.

Conference proceedings
On 16 September 2011 we searched the Conference Papers Index (from 1982) and Conference Proceedings Citation Index - Science (CPCI-S) (from 1990) for relevant studies using the search strategies in Appendix 9 and Appendix 7, respectively.

References lists
We scanned the bibliographies of the included studies and published reviews for relevant references. We used SCI-EXPANDED to identify further papers that cited the included studies, and we scanned them for relevant studies.

Unpublished literature
We contacted the original researchers of the most recent studies to ask if they knew of any other relevant trials, but they did not respond to these queries.

Language
We did not impose any language restrictions.

Adverse Effects
We did not run separate searches for adverse effects, but we extracted relevant data from the included studies.

Data collection and analysis

Selection of studies
Two authors (CC, GK) independently checked titles and abstracts identified from the searches. The authors were not blinded to the names of original researchers, journals, or institutions. If it was clear from the abstract that the study did not refer to a RCT on genital lichen sclerosus (LS), it was excluded. The same two authors independently assessed the full-text version of each remaining study to determine whether it met the pre-defined selection criteria. Disagreement was resolved by discussion. We listed the studies that were excluded, after reading the full text, and reasons for exclusion in the ‘Characteristics of excluded studies’ table.

Data extraction and management
Two authors (CC, GK) independently extracted the data using a specialised data extraction form. Discrepancies were resolved by discussion with another author (FW). One author (CC) entered the data into Review Manager (RevMan).

Assessment of risk of bias in included studies
We evaluated the following components since there is some evidence that these are associated with biased estimates of treatment effect (Higgins 2011):
- adequacy of random sequence generation;
- allocation concealment - it was considered “adequate” if the assignment could not be foreseen;
- blinding - adequacy of prevention of knowledge of the allocated interventions;
- incomplete outcome data - whether this was adequately addressed; and
- whether the study was free of selective reporting (if the trial study protocol was available, were all prespecified outcomes reported? If the trial study protocol was unavailable, were all primary outcomes of our interest (global degree of improvement rated by participants or researchers and adverse drug reactions that were severe enough to require withdrawal of treatment) reported?).
In addition we reported other potential threats to validity:
- the degree of certainty that the participants had LS;
- the baseline assessment of the participants for age, duration of disease, location involved, and severity of LS;
- drug identity, source, dose, duration of treatments, and adequacy of instructions;
- whether the outcome measures were described and their assessment was standardised;
- whether previous treatments for LS were discontinued;
- whether concomitant treatments for LS were permitted or standardised; and
- the use and appropriateness of statistical analyses where tabulated data could not be extracted from the original publication.
Measures of treatment effect
We expressed the results as risk ratios (RR) and 95% confidence intervals (CI) for dichotomous outcomes, and standardised mean difference (SMD) and 95% CI for ordinal outcomes. We also expressed the dichotomous results as number needed to treat (NNT) and number needed to treat to harm (NNH), where appropriate, for a range of plausible control event rates. Participant-rated global degree of improvement was the primary outcome measure when available. If unavailable, the investigator-rated global degree of improvement was used. Both measures were reported where both were available. We did not combine the two measures.

Unit of analysis issues
Where there were multiple intervention groups within a trial, we made pair-wise comparisons of an intervention versus no treatment, placebo, and another intervention. We analysed internally-controlled trials using appropriate techniques for paired designs, and these studies were not be pooled with studies of other designs.

Dealing with missing data
We contacted the original researchers of studies less than 15 years old for missing data. If participant dropout led to missing data, we had planned to conduct an intention-to-treat analysis. For dichotomous outcomes we would have regarded participants with missing outcome data as treatment failures and included them in the analysis. For continuous outcomes we would have carried forward the last recorded value for participants with missing outcome data. Where high levels of missing data were seen within the analyses, we would have conducted sensitivity analyses to assess the robustness of the results from the approach described above, by comparing the results with those which had excluded the missing data from the analyses. However, we did not carry out these planned analyses because the majority of the included studies did not report the level of participant dropout.

Assessment of heterogeneity
We assessed statistical heterogeneity using the I² statistic. We assessed clinical heterogeneity arising from the study design (e.g. parallel or cross-over studies), interventions, participants, and outcome measures. If the I² statistic was less than 80% with reasonable clinical homogeneity, we applied meta-analysis techniques as appropriate.

Assessment of reporting biases
We planned to test publication bias by using a funnel plot if adequate data for a topical intervention were available. However, the limited number of trials meant it was not possible to do this test.

data synthesis
For studies on a similar type of intervention (e.g. topical testosterone) we applied meta-analysis using a random-effects model to calculate a weighted treatment effect across trials when the I² statistic was 80% or less with reasonable clinical homogeneity. Where it was inappropriate or impossible to perform a meta-analysis, we summarised the data for each trial.

Subgroup analysis and investigation of heterogeneity
We discussed similarities and differences in the study design, interventions, participants, and outcome measures of the included RCTs. We planned to perform subgroup analyses accordingly. With regard to the participants, we planned to conduct subgroup analyses of the following:
- genital LS in adult women;
- genital LS in adult men;
- genital LS in female children; and
- genital LS in male children.

But the number of included trials was too few to conduct these planned subgroup analyses.

Sensitivity analysis
A sensitivity analysis to examine the effects of excluding poor quality studies was planned but not conducted, because of the limited number of trials for each intervention.

Other
A consumer (FB) was involved throughout the review process to help improve the relevance and readability of the final review.

RESULTS

Description of studies
See: Characteristics of included studies; Characteristics of excluded studies; Characteristics of ongoing studies.

Results of the search
Our search identified 312 citations, of which 18 were considered potentially eligible (Bracco 1993; Cattaneo 1992; Cattaneo 1996; Chari 1994; Diakomanolis 2002; Friedrich 1971; Goldstein 2011; Kiss 2001; Li 2004; NCT00757874; Origoni 1996; Paslin 1991; Paslin 1996; Sideri 1994; Skierlo 1987; Sotiriou 2008; Zarcone 1996; Zhu 2006).
Included studies

This review included 7 studies (8 publications), with a total of 249 participants covering 6 treatments: We included 7 studies that met our inclusion criteria (Bracco 1993; Cattaneo 1996; Goldstein 2011; Kiss 2001; Paslin 1991; Paslin 1996; Sideri 1994). One paper (Cattaneo 1992) was a duplicate publication of part of another study (Bracco 1993); so we, therefore, combined the data reported by the two papers. The details of the included studies are described in the 'Characteristics of included studies' tables.

Design

All of the included studies were RCTs, with two being cross-over RCTs (Paslin 1991; Paslin 1996).

Sample sizes

The number of participants in the included studies ranged from 5 (Paslin 1991; Paslin 1996) to 79 (Bracco 1993). The two cross-over trials only included 5 women each (Paslin 1991; Paslin 1996). Four other trials included 16 to 20 participants in each arm (Bracco 1993; Cattaneo 1996; Goldstein 2011; Kiss 2001). The other trial included 30 and 28 women in the treatment and placebo groups, respectively (Sideri 1994).

Setting

The setting of all of the included studies was either a single hospital or a specialist clinic. All of the studies were conducted in either Europe or the USA.

Participants

The participants were adult women in the majority of the studies (Bracco 1993; Cattaneo 1996; Goldstein 2011; Paslin 1991; Paslin 1996; Sideri 1994). Only one study included boys as participants (Kiss 2001).

Interventions

We only found RCTs on topical clobetasol, mometasone, testosterone, dihydrotestosterone, progesterone, and pimecrolimus. One study (Cattaneo 1996) investigated the effectiveness of topical testosterone propionate as maintenance therapy. All of the interventions were single therapy. The comparator was placebo in five studies (Bracco 1993; Cattaneo 1996; Kiss 2001; Paslin 1991; Sideri 1994). The placebo was a vehicle (e.g. the petrolatum base of the ointment or cream without the active ingredient) and not truly inert. One of the trials compared three topical interventions (clobetasol propionate, testosterone, and progesterone) against placebo (Bracco 1993). The other two studies used an active control: One compared testosterone and dihydrotestosterone (Paslin 1996), while the other compared pimecrolimus and clobetasol propionate (Goldstein 2011).

Outcomes

All of the studies included participant-rated change in symptoms and investigator-rated improvement of gross appearance. We originally planned a time point of outcome measurement at three to six months into therapy, but in one included trial outcomes were measured five weeks into therapy (Kiss 2001), while in another trial, measurement was made one year into therapy (Sideri 1994). We included the two trials, and the validity of this review did not appear to be affected (see Differences between protocol and review).

Two studies did not report adverse drug reactions (Paslin 1991; Paslin 1996), while one study did not fully report adverse drug reactions (Bracco 1993).

Funding source

One study was supported by a pharmaceutical company (Goldstein 2011), while the other six studies did not report any funding source (Bracco 1993; Cattaneo 1996; Kiss 2001; Paslin 1991; Paslin 1996; Sideri 1994).

Excluded studies

Of the 18 potentially eligible studies, we excluded 9 when we had looked at them in detail. The reasons for exclusion are listed in the 'Characteristics of excluded studies' tables.

Ongoing studies

We identified three ongoing trials; the available data are in the 'Characteristics of ongoing studies' tables.

Risk of bias in included studies

Many of the elements assessed in the risk of bias analysis were lacking in most of the studies (see 'Characteristics of included studies' tables). Our judgements about each methodological quality item for each included study are summarised in Figure 1, and our judgements about each methodological quality item presented as percentages across all of the included studies are summarised in Figure 2.
Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality item for each included study.

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Blinding (performance bias and detection bias)</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Degree of certainty that the participants have LS</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Baseline assessment of the participants</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Drug identity, source, dose, duration of treatments, and adequacy of instructions</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Description and standardization of outcome measures</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Discontinuation of previous treatments</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Permission or standardization of concomitant treatments</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Use and appropriateness of statistical analyses where tabulated data could not be extracted from the original publication</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
</tbody>
</table>
Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality item presented as percentages across all included studies.

**Allocation**

**Random sequence generation**

Two studies used an adequate method of randomisation by coin tossing (Paslin 1991; Paslin 1996). All of the other six studies did not describe the process of randomisation (Bracco 1993; Cattaneo 1996; Goldstein 2011; Kiss 2001; NCT00757874; Sideri 1994).

**Allocation concealment**

Allocation could not be foreseen in the two studies using coin tossing for randomisation (Paslin 1991; Paslin 1996), as, in both of these studies, allocation was done by the office technician after the participants were enrolled.

It is unclear if allocation was concealed in the other six studies (Bracco 1993; Cattaneo 1996; Goldstein 2011; Kiss 2001; NCT00757874; Sideri 1994).

**Blinding**

In four studies (Goldstein 2011; Paslin 1991; Paslin 1996; Sideri 1994), both the investigators and participants were blinded. In another study (Cattaneo 1996) the investigator was blinded to the allocated treatments.

**Incomplete outcome data**

Only two studies reported withdrawal and dropout (Goldstein 2011; Kiss 2001).

**Selective reporting**

Four studies reported all of the three prespecified primary outcomes (Cattaneo 1996; Goldstein 2011; Kiss 2001; Sideri 1994). One trial did not fully report or fully describe adverse drug reactions (Bracco 1993), and two other trials did not report adverse drug reactions at all (Paslin 1991; Paslin 1996).

**Other potential sources of bias**

**Certainty of diagnosis of LS**

The diagnosis was confirmed by biopsy in all of the included studies (Bracco 1993; Cattaneo 1996; Goldstein 2011; Kiss 2001; Paslin 1991; Paslin 1996; Sideri 1994).

**Baseline assessment of participants**

Baseline assessment of the participants was not performed in five studies (Bracco 1993; Cattaneo 1996; Goldstein 2011; Kiss 2001; Sideri 1994). The participants in the two cross-over trials were all middle- to old-aged women (Paslin 1991; Paslin 1996).
Drug identity, source, dose, duration of treatments, and adequacy of instructions

The intervention was standardised in all of the included studies (Bracco 1993; Cattaneo 1996; Goldstein 2011; Kiss 2001; Paslin 1991; Paslin 1996; Sideri 1994).

Description and standardisation of outcome measures

Various scoring systems of symptoms and gross appearance were used, but they were only described in four studies (Bracco 1993; Cattaneo 1996; Goldstein 2011; Kiss 2001). One study used a scoring system to assess clinical and symptomatic status, but it did not provide relevant details (Sideri 1994). Another trial only standardised one outcome measure, vulval itching, by using a scoring system, but it did not report the rating results (Paslin 1996). Another trial by the same author did not describe the standardisation of outcome measures (Paslin 1991).

Discontinuation of previous treatments

Previous treatments were discontinued in five studies (Bracco 1993; Cattaneo 1996; Goldstein 2011; Paslin 1991; Paslin 1996). In one study, all of the participants received an initial two-week course of topical antibiotic/corticosteroid cream before allocation (Sideri 1994). Another study did not report if previous treatments were discontinued (Kiss 2001).

Permission or standardisation of concomitant treatments

None of the studies provided relevant descriptions of concomitant treatments (Bracco 1993; Cattaneo 1996; Goldstein 2011; Kiss 2001; Paslin 1991; Paslin 1996; Sideri 1994).

Use and appropriateness of statistical analyses where tabulated data could not be extracted from the original publications

Two studies used appropriate statistical analyses (Goldstein 2011; Sideri 1994). Three studies did not use appropriate non-parametric statistical methods (e.g. Wilcoxon signed rank test) for ranked outcome data (Bracco 1993; Cattaneo 1996; Kiss 2001). No statistical analyses were appropriate for the very small sample used in the two cross-over studies (Paslin 1991; Paslin 1996).

Effects of interventions

We have addressed our prespecified outcomes, in relation to the interventions listed above, under Types of interventions. Our prespecified primary outcomes included the following:

1) Participant-rated improvement of symptoms or remission of symptoms (in terms of quality of life, pain, itching, and less pain with intercourse).

2) Investigator-rated global degree of improvement (in terms of pallor, purpura, hyperkeratosis, ulceration, erosion, erythema, sclerosis, and scarring).

3) Adverse drug reactions severe enough to require withdrawal of treatment, including severe skin irritation or infection.

All of the included trials, but one (Kiss 2001), reported participant-rated improvement in symptoms. Only one trial specifically assessed pain with intercourse (Paslin 1996). All seven included studies reported investigator-rated improvement of gross appearance.

Five trials (Cattaneo 1996; Goldstein 2011; Kiss 2001; Sideri 1994; Bracco 1993) reported adverse drug reactions severe enough to require withdrawal of treatment, but the study by Bracco 1993 omitted reporting relevant data regarding progesterone. Two trials (Paslin 1991; Paslin 1996) did not report this primary outcome. Our prespecified secondary outcomes included the following:

1) Adverse drug reactions that were not severe enough to require cessation of treatment, such as mild skin irritation, atrophy, or telangiectasia.

2) Duration of remission or prevention of subsequent flares, or both.

3) Development of genital squamous cell carcinoma (SCC) or genital intraepithelial neoplasia.

Four trials (Cattaneo 1996; Goldstein 2011; Kiss 2001; Bracco 1993) reported adverse drug reactions not severe enough to require withdrawal of treatment. The study by Bracco 1993 addressed this outcome after applying clobetasol propionate and testosterone, but it did not report adverse drug reactions to progesterone. Two of the included studies did not report this outcome at all (Paslin 1991; Paslin 1996).

None of the included studies reported the other two secondary outcomes.

Topical corticosteroids

The efficacy of only two topical corticosteroids, clobetasol propionate 0.05% (very potent) and mometasone furoate 0.05% ointment (potent), were assessed in two of the included studies (Bracco 1993; Kiss 2001).

Clobetasol propionate vs placebo

In the study by Bracco 1993, the efficacy of topical clobetasol propionate was compared to placebo after three months’ application. Clobetasol propionate was significantly better than placebo in relation to the following outcomes: 'participant-rated improvement or remission of symptoms' (RR 2.85, 95% CI 1.45 to 5.61) (see Analysis 1.1) and ‘investigator-rated global degree of improvement’ (SMD 5.74, 95% CI 4.26 to 7.23) (see Analysis 1.2). The study found no events of adverse drug reactions (e.g. predisposition to infection, worsening of skin atrophy, and contact dermatitis) in either the clobetasol propionate or placebo group.
Mometasone furoate vs placebo
In the study by Kiss 2001, the efficacy of topical mometasone furoate was compared to placebo after five weeks' application. With regard to the outcome 'investigator-rated change in clinical score of phimosis from baseline', the mean clinical grade of phimosis improved in the mometasone furoate group, but worsened in the placebo group (SMD -1.04, 95% CI -1.77 to -0.31) (see Analysis 2.1). No local or systemic adverse drug reactions occurred in either group.

Topical androgens
The efficacy of two androgens, testosterone propionate (2% cream) and dihydrotestosterone (2% cream), were studied in five of the included studies (Bracco 1993; Cattaneo 1996; Paslin 1991; Paslin 1996; Sideri 1994).

Testosterone vs placebo
The study period of the Bracco 1993 and Sideri 1994 studies was three months and one year, respectively. In the studies by Bracco 1993 and Sideri 1994, there was no significant difference in the efficacy of testosterone compared to placebo in relation to the outcome 'participant-rated improvement or remission of symptoms' when the 2 studies were combined (RR 1.21, 95% CI 0.56 to 2.64) (see Analysis 3.1). The outcome 'investigator-rated improvement of gross appearance' was only reported by Bracco 1993, but there was no significant difference between the 2 groups (SMD 0.42, 95% CI -0.21 to 1.06) (see Analysis 3.2). No significant difference in severe adverse drug reactions was found between the testosterone and placebo groups when the 2 studies were combined (RR 5.19, 95% CI 0.62 to 43.19) (see Analysis 3.3).

Dihydrotestosterone vs placebo
A very small cross-over trial (Paslin 1996) randomised five participants to receive either dihydrotestosterone or placebo for three months, before switching to the other for three months. The trial lacked a wash-out period, and we, thus, used only the data from the first period before cross-over for analysis. The trial did not find significant differences in efficacy between the 2 androgens in relation to the outcomes 'participant-rated remission of itching' (RR 0.25, 95% CI 0.01 to 4.23) (see Analysis 6.1) and 'investigator-rated gross improvement' (RR 1.00, 95% CI 0.53 to 1.87) (see Analysis 6.2). Of the two women who were sexually active and received testosterone before cross-over, one did not have dyspareunia after treatment. Both of the women who received dihydrotestosterone before cross-over were not sexually active. Therefore, we could not compare the effects of the two androgens on dyspareunia.

Testosterone vs dihydrotestosterone
A very small cross-over trial (Paslin 1996) randomised five participants to receive either testosterone or dihydrotestosterone for three months, before switching to the other for three months. The trial lacked a wash-out period, and we, thus, used only the data from the first period before cross-over for analysis. The trial did not find significant differences in adverse drug reactions between the two androgens with regard to our primary outcome 'adverse drug reactions that were severe enough to require withdrawal of treatment' (RR 3.00, 95% CI 0.13 to 69.52) (see Analysis 5.3) or our secondary outcome 'adverse drug reactions that were not severe enough to require cessation of treatment' (RR 7.00, 95% CI 0.38 to 127.32) (see Analysis 5.4).

Testosterone vs placebo as maintenance therapy
The study by Cattaneo 1996 investigated whether topical testosterone could control the symptoms and signs of vulval LS after an initial 24-week treatment with 0.05% clobetasol propionate cream. The study found that testosterone when used as maintenance therapy for 24 weeks worsened the symptoms (P < 0.05), while the vehicle-based placebo caused no change in symptoms or gross appearance (see Analysis 7.1 and Analysis 7.2). The Mann-Whitney U test was used to compare the scores before and after the interventions. However, the Wilcoxon signed rank test should be used to compare the paired data. No adverse drug reaction events 'severe enough to require withdrawal of treatment' occurred in either of the two groups. There was no significant difference in adverse drug reactions 'severe enough to require withdrawal of treatment' in either the testosterone or the placebo groups (RR 9.00, 95% CI 0.52 to 154.56) (see Analysis 7.3).

Testosterone vs clobetasol propionate
The study by Bracco 1993 found that after 3 months' application, testosterone was significantly less effective than clobetasol propionate with regard to the following outcomes: 'participant-rated improvement or remission of symptoms' (RR 0.67, 95% CI 0.45 to 0.98) (see Analysis 5.1) and 'investigator-rated global degree of improvement' (SMD -1.81, 95% CI -2.56 to -1.06) (see Analysis 5.2).

Testosterone vs placebo as maintenance therapy
The study by Cattaneo 1996 investigated whether topical testosterone could control the symptoms and signs of vulval LS after an initial 24-week treatment with 0.05% clobetasol propionate cream. The study found that testosterone when used as maintenance therapy for 24 weeks worsened the symptoms (P < 0.05), while the vehicle-based placebo caused no change in symptoms or gross appearance (see Analysis 7.1 and Analysis 7.2). The Mann-Whitney U test was used to compare the scores before and after the interventions. However, the Wilcoxon signed rank test should be used to compare the paired data. No adverse drug reaction events ‘severe enough to require withdrawal of treatment’ occurred in either of the two groups. There was no significant difference in adverse drug reactions ‘severe enough to require withdrawal of treatment’ in either the testosterone or the placebo groups (RR 9.00, 95% CI 0.52 to 154.56) (see Analysis 7.3).
for either ‘participant-rated improvement or remission of symptoms’ (RR 1.58, 95% CI 0.72 to 3.50) (see Analysis 8.1) or for ‘investigator-rated global degree of improvement’ (SMD 0.34, 95% CI -0.29 to 0.97) (see Analysis 8.2).

**Topical immunomodulators (tacrolimus, pimecrolimus, ciclosporin)**

One study tested the efficacy and safety of pimecrolimus (1% cream) against clobetasol propionate (0.05% cream) after 12 weeks’ application (Goldstein 2011). Both were effective in relieving pruritus and burning/pain, and there were no significant differences between pimecrolimus and clobetasol propionate in relieving pruritus and burning/pain: change in pruritus (SMD -0.33, 95% CI -0.99 to 0.33) (see Analysis 9.1), change in burning/pain (SMD 0.03, 95% CI -0.62 to 0.69) (see Analysis 9.2). Investigator Global Assessment showed both preparations were effective. However, pimecrolimus was less effective than clobetasol propionate in relation to the ‘investigator-rated global degree of improvement’ (SMD -1.64, 95% CI -2.40 to -0.87) (see Analysis 9.3). No adverse drug reactions occurred in either the pimecrolimus or clobetasol propionate group.

**DISCUSSION**

**Summary of main results**

The very potent topical steroid, clobetasol propionate 0.05%, was found to be significantly more effective than placebo in treating genital lichen sclerosus (SMD 5.74, 95% CI 4.26 to 7.23) (see Goldstein 2011). This concentration of mometasone furoate was applied once daily in this trial. Thus, the comparable efficacy of pimecrolimus might have been underestimated. On the other hand, pimecrolimus was less effective than clobetasol propionate in relation to the outcome ‘investigator-rated global degree of improvement’ (SMD -1.64, 95% CI -2.40 to -0.87). Furthermore, on histopathological examinations, clobetasol propionate was superior to pimecrolimus in improving inflammation (P = 0.015). However, this was not a prespecified clinical outcome of interest for our review (Goldstein 2011).

**Overall completeness and applicability of evidence**

All but one study enrolled adult women with vulval lichen sclerosus as participants (Bracco 1993; Cattaneo 1996; Goldstein 2011; Paslin 1991; Paslin 1996; Sideri 1994). Only one study enrolled boys with penile lichen sclerosus as participants (Kiss 2001). This limitation compromises the external validity of the current evidence.

The efficacy of only two different topical corticosteroids, clobetasol propionate and mometasone furoate, has been demonstrated in RCTs (Bracco 1993; Kiss 2001). The concentration of mometasone furoate used in the trial was 0.05% (Kiss 2001), which was half the usual concentration of 0.1%. It is likely that other potent or moderate topical corticosteroids are effective in treating lichen sclerosus, but relevant RCTs are unavailable.

The regimen of clobetasol propionate varied among the trials. In 1 trial (Bracco 1993), clobetasol propionate 0.05% was applied twice daily for 1 month then once daily for 2 months. In another trial comparing pimecrolimus and clobetasol propionate, clobetasol propionate was applied once daily (Goldstein 2011).

We did not find RCTs comparing the efficacy of different regimens of topical clobetasol propionate in treating genital lichen sclerosus. Two previous RCTs of halcinonide (another very potent topical corticosteroid) on extragenital skin found that once-daily application of halcinonide 0.1% cream was as effective as thrice-daily application of the same cream in treating psoriasis and atopic dermatitis (Fredriksson 1980; Sudilovsky 1981). However, thrice-daily application had a more rapid onset of action (Fredriksson 1980) and was superior to once-daily application, especially for severe psoriasis (Sudilovsky 1981). In an uncontrolled before-and-
after study on topical clobetasol propionate 0.05% cream for treating vulval lichen sclerosus in 15 women (Dalziel 1991), the cream was applied twice daily for 12 weeks and had remarkable efficacy on symptoms and clinical appearance in 13 women who completed the study. Randomised controlled trials comparing the efficacy of various regimens of topical clobetasol propionate should be conducted.

One trial found pimecrolimus effective in treating genital lichen sclerosus (Goldstein 2011); however, it is only licensed as a second-line therapy for atopic dermatitis, and it is not indicated for use in children younger than two years of age (Novartis 2010). We identified an ongoing trial on tacrolimus (NCT00757874), but the author did not provide us with any data, despite repeated requests, so we are unable to include this study in the current review.

The study period of the included studies ranged from five weeks to one year. None of them were able to assess the long-term effects on the development of squamous cell carcinoma or genital intraepithelial neoplasia. This question may only be answered by trials with very long follow-up periods.

The scarring of lichen sclerosus may cause fusion of the labia, narrowing of the vaginal introitus, and burying of the clitoris. Thus, women may have dyspareunia (painful sexual intercourse) or less pleasurable sex, and the quality of sex life should be a clinical outcome. However, only a very small study ever specifically examined this outcome (Paslin 1996).

Quality of the evidence

The sample size of all seven studies was small; the total number of participants was 249. The small sample size may lead to insufficient statistical power to detect significant differences in outcomes. However, most of the efficacy estimates were quite precise except for the two small cross-over trials (Paslin 1991; Paslin 1996).

Most of the studies were published before 1996, when the Consolidated Standards of Reporting Trials (CONSORT) Statement was proposed. Therefore, most studies did not provide a full description of the methods of random sequence generation, allocation concealment, blinding, withdrawal or dropout, and permission or standardisation of concomitant treatments (Bracco 1993; Cattaneo 1996; Paslin 1991; Paslin 1996; Sideri 1994). Although two studies were published after 1996 (Goldstein 2011; Kiss 2001), they did not report the methods of random sequence generation, allocation concealment, and permission or standardisation of concomitant treatments.

A drawback of the included studies was the use of inappropriate statistical methods (Figure 1). Three studies used parametric methods like the Student's t-test to compare the scores before and after interventions (Bracco 1993; Cattaneo 1996; Kiss 2001), but non-parametric methods, such as the Wilcoxon signed rank test, should be used in such circumstances. However, it is unclear whether the study results would change substantially if the trialists had used non-parametric tests. The Cattaneo 1996 trial compared the scores before and after topical testosterone and placebo, respectively. However, it did not make a direct comparison of the efficacy of the two tested interventions. Two studies did not report numerical data of the change in symptoms and gross appearance, nor use statistical analysis to assess the efficacy of interventions (Paslin 1991; Paslin 1996). We did not use histopathological change as an outcome measure in this review, because it is not a clinical outcome relevant to the well-being of affected people. Six studies included histopathological changes as an outcome (Bracco 1993; Cattaneo 1996; Goldstein 2011; Paslin 1991; Paslin 1996; Sideri 1994). In most of these studies, the histopathological changes were in line with the clinical outcomes. The exception was one study comparing topical testosterone and placebo in which the symptoms were reported to improve in both groups, but gross appearance or histological findings did not change (Sideri 1994).

Potential biases in the review process

All but one of the included studies were published more than a decade ago. Therefore, some authors did not keep the original data and could not provide missing data for our analyses. For example, the authors of one study could not find the original data and provide us with the standard deviation (SD) of the mean change in gross appearance (Bracco 1993). We, thus, calculated the data based on the information reported in the paper, which might reduce the precision of our effect estimates.

Agreements and disagreements with other studies or reviews

A guideline (Neil 2010) and a review (Pugliese 2007) on the management of lichen sclerosus were published prior to our review. The guideline searched MEDLINE and EMBASE from 2002 to 2009 (Neil 2010), and the review searched PubMed, MEDLINE, and other electronic databases between 1950 and 2006 (Pugliese 2007). However, neither of them were systematic reviews because of a lack of critical appraisal (e.g. assessment of 'Risk of bias') of the included studies. The British Association of Dermatologists’ 2010 guidelines for the management of lichen sclerosus (Neil 2010) were in line with our findings in this review that very potent topical corticosteroids are the mainstay of treatments for genital lichen sclerosus. The guidelines also stated that there was a lack of evidence for the use of topical testosterone or other hormonal treatments. They did not recommend topical calcineurin inhibitors as first-line treatment because of case reports of the development of squamous cell carcinoma following the use of these drugs and lack of relevant long-term safety data.
The review published in 2007 (Pugliese 2007) also agreed with our review that very potent topical corticosteroids are the primary topical treatments for genital lichen sclerosus, but it had no data on topical calcineurin inhibitors.

**AUTHORS’ CONCLUSIONS**

**Implications for practice**

The current evidence indicates that topical clobetasol propionate 0.05% is effective in treating genital lichen sclerosus. Topical mometasone furoate has been shown to be effective in boys with penile lichen sclerosus. It is unclear whether other topical corticosteroids are effective. The current evidence found no significant difference between topical pimecrolimus and clobetasol propionate in the efficacy of relieving symptoms, but the former is less effective than the latter in improving gross appearance and reducing inflammation.

**Implications for research**

The current evidence is limited, and further studies are required to fill in some gaps in knowledge.

Firstly, we need RCTs determining the potency and regimen (e.g. frequency and duration of application) of topical corticosteroids that have adequate therapeutic efficacy but with the least desirable adverse effects (e.g. infections and skin thinning).

Secondly, we only found that a limited number of topical interventions (e.g. topical corticosteroids), sex hormones, and calcineurin inhibitors have been tested. Randomised controlled trials testing other interventions (see Types of interventions) are awaited.

Thirdly, one of our secondary outcomes, ‘duration of remission or prevention of subsequent flares’, should be included in future RCTs, although this means that long follow-up periods are required.

Fourthly, it remains unknown whether effective treatments can reduce the risk of development of genital squamous cell carcinoma (SCC) or genital intraepithelial neoplasia from lichen sclerosus. Randomised controlled trials of adequate length to answer this question should be conducted. Given the 5% risk of SCC development in women with genital lichen sclerosus, a sample size of at least 984 treated and 984 untreated participants is needed to determine if a treatment can halve this risk, based on a significance level of 0.05 and power of 0.8.

Last, but not least, the quality of the sex lives of people with this condition should be examined in future trials.

**ACKNOWLEDGEMENTS**

The Cochrane Skin Group editorial base would like to thank the following people who commented on this update: our Key Editor Michael Bigby, our Statistical Editor Jo Leonardi-Bee, our Methodological Editor Sarah Garner, Hazel Bell and Sallie Neill who were the clinical referees, and Jack Tweed who was the consumer referee.

References to studies included in this review

**Bracco 1993** *(published data only)*


**Cattaneo 1996** *(published data only)*


**Goldstein 2011** *(published and unpublished data)*


**Kiss 2001** *(published data only)*


**Paslin 1991** *(published data only)*


**Paslin 1996** *(published data only)*

References to studies excluded from this review

Chari 1994  (published data only)

Diakomanolis 2002  (published data only)

Friedrich 1971  (published data only)

Li 2004  (published data only)

Origoni 1996  (published data only)

Sotiriou 2008  (published data only)

Zarcone 1996  (published data only)

Zhu 2006  (published data only)

References to ongoing studies

NCT00757874  (unpublished data only)

NCT01126255  (unpublished data only)

NCT01400022  (unpublished data only)

Additional references

Azurdia 1999

Baldo 2010

BNF 2010

Bohn 2003

Boms 2004

Borstein 1998

Brownstein 1973

Carli 1992
Topical interventions for genital lichen sclerosus (Review)

Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Loden 1999

Marren 1995

Mazdisnian 1999

Meffert 1995

Meyrick 1988

Neill 2010

Novartis 2010

Oyama 2003

Patel 2009

Powell 1999

Powell 2001

Pugliese 2007

Reichrath 2002

Renaud-Vilmer 2004

Shankar 1999

Sherman 2010

Simonart 2008

Sudilovsky 1981

Tasker 2003

Tremaine 1989

Virgili 1995

Wallace 1971

Wang 2010

* Indicates the major publication for the study.
### Characteristics of included studies (ordered by study ID)

#### Bracco 1993

<table>
<thead>
<tr>
<th>Methods</th>
<th>This is a randomised controlled trial.</th>
</tr>
</thead>
</table>
| **Participants** | ● 79 women with long-standing, biopsy-proven vulval LS  
● Mean age = 57 years (range 27 to 83)  
● Mean duration of disease = 33 months (range 2 to 120) |
| **Interventions** | 4 topical drugs including the following:  
A: testosterone (2%);  
B: progesterone (2%);  
C: clobetasol propionate (0.05%); and  
D: a cream-based preparation.  
All topical drugs were applied twice daily for 3 months, except clobetasol propionate which was applied twice daily for 1 month then once daily for 2 months |
| **Outcomes** | **Outcomes of the trial**  
1) Symptoms (itching, burning, pain, and dyspareunia)  
2) Gross appearance (hyperkeratosis, purpura, thickness of plaques, atrophy, and erosions)  
3) Histological features (epidermal atrophy, oedema, intensity of inflammatory infiltrate, and fibrosis)  
All were classified according to a 0- to 3-point scoring system |
| **Notes** | Setting: university hospital  
Country: Italy  
Funding source: not reported |

#### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>There was no description of the process of randomisation.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>There was no description of the allocation concealment.</td>
</tr>
<tr>
<td>Blinding (performance bias and detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>There was no description of blinding.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>There was no description of withdrawal or dropout.</td>
</tr>
</tbody>
</table>
### Bracco 1993

<table>
<thead>
<tr>
<th>Selective reporting (reporting bias)</th>
<th>Unclear risk</th>
<th>Symptoms and gross appearance were assessed, but adverse drug reactions were not fully described</th>
</tr>
</thead>
<tbody>
<tr>
<td>Degree of certainty that the participants have LS</td>
<td>Low risk</td>
<td>LS was proven by biopsy.</td>
</tr>
<tr>
<td>Baseline assessment of the participants</td>
<td>Unclear risk</td>
<td>No comparisons of baseline characteristics between the 2 groups were made.</td>
</tr>
<tr>
<td>Drug identity, source, dose, duration of treatments, and adequacy of instructions</td>
<td>Low risk</td>
<td>The treatments were standardised.</td>
</tr>
<tr>
<td>Description and standardisation of outcome measures</td>
<td>Low risk</td>
<td>A 0-to-3 point scoring system of symptoms was used which included gross appearance and histological features</td>
</tr>
<tr>
<td>Discontinuation of previous treatments</td>
<td>Low risk</td>
<td>There was no use of a topical corticosteroid for at least 3 months preceding the trial</td>
</tr>
<tr>
<td>Permission or standardisation of concomitant treatments</td>
<td>Unclear risk</td>
<td>There was no relevant description.</td>
</tr>
<tr>
<td>Use and appropriateness of statistical analyses where tabulated data could not be extracted from the original publication</td>
<td>Unclear risk</td>
<td>The only outcome we could not extract tabulated data for was ‘investigator-rated global degree of improvement’. The trialist used Student’s t-test to compare the scores before and after treatments, but Wilcoxon signed rank test should be used</td>
</tr>
</tbody>
</table>

### Cattaneo 1996

<table>
<thead>
<tr>
<th>Methods</th>
<th>This was a randomised controlled trial.</th>
</tr>
</thead>
</table>
| Participants | - 32 women with biopsy-proven vulval LS after 24 weeks of treatment with 0.05% clobetasol propionate cream  
- Mean age = 60 years, median age = 58 (range 28 to 85)  
- Mean duration of disease = 22.7 months (range 2 to 96)  
- 28 women (87.5%) were postmenopausal |
| Interventions | A: testosterone propionate 2%  
B: placebo (petrolatum vehicle alone)  
These were taken once daily as maintenance therapy for 24 weeks |
| Outcomes | **Outcomes of the trial**  
1) Symptoms (itching, burning, soreness, and dryness)  
2) Gross aspects (hyperkeratosis, atrophy, and sclerosis)  
3) Histological features (epidermal atrophy, oedema, inflammatory infiltrate, and fibro- |
All were evaluated using a 0- to 3-point scoring system.

Notes
Setting: university hospital
Country: Italy
Funding source: not reported

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>There was no description of the process of randomisation.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>There was no description of the allocation concealment.</td>
</tr>
<tr>
<td>Blinding (performance bias and detection bias)</td>
<td>Low risk</td>
<td>The investigators were blinded to the treatment used by each participant</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>There was no description of withdrawal or dropout.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Symptoms, gross aspects, and adverse drug reactions were reported</td>
</tr>
<tr>
<td>Degree of certainty that the participants have LS</td>
<td>Low risk</td>
<td>LS was proven by biopsy.</td>
</tr>
<tr>
<td>Baseline assessment of the participants</td>
<td>Unclear risk</td>
<td>This was not performed.</td>
</tr>
<tr>
<td>Drug identity, source, dose, duration of treatments, and adequacy of instructions</td>
<td>Unclear risk</td>
<td>The treatments were standardised.</td>
</tr>
<tr>
<td>Description and standardisation of outcome measures</td>
<td>Low risk</td>
<td>A 0-to-3 point scoring system of symptoms was used which included gross aspects and histological features</td>
</tr>
<tr>
<td>Discontinuation of previous treatments</td>
<td>Low risk</td>
<td>All of the women discontinued previous treatments.</td>
</tr>
<tr>
<td>Permission or standardisation of concomitant treatments</td>
<td>Unclear risk</td>
<td>There was no relevant description.</td>
</tr>
<tr>
<td>Use and appropriateness of statistical analyses where tabulated data could not be extracted from the original publication</td>
<td>Unclear risk</td>
<td>The Mann-Whitney U test was used to compare the scores before and after treatments, but the Wilcoxon signed rank test should be used</td>
</tr>
</tbody>
</table>
Goldstein 2011

<table>
<thead>
<tr>
<th>Methods</th>
<th>This was a randomised controlled trial.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>• 38 women with biopsy-proven vulval LS</td>
</tr>
</tbody>
</table>
| Interventions | A: pimecrolimus cream 1% twice daily  
B: alternate clobetasol cream 0.05% (in the evening) and vehicle cream (in the morning)  
These were taken for 12 weeks. |
| Outcomes | **Primary outcomes of the trial**  
1) Histopathological change in inflammation (0 to 4 scale)  
**Secondary outcomes of the trial**  
1) Change from baseline in pruritus (VAS-PR) and burning/pain (VAS-BP) rated by participants using 0 to 10 point visual analogue scale questionnaires  
2) Investigator’s Global Assessment of the severity of disease (0 to 3 scale), clinical evaluation of lichenification (0 to 3 scale), and clinical valuation of ulceration/fissuring (0 to 3 scale) |
| Notes | Setting: specialist clinic (Center for Vulvovaginal Disorders)  
Country: US  
Funding source: Novartis Pharmaceuticals Co. |

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>There was no description of the process of randomisation.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>There was no description of the allocation concealment.</td>
</tr>
<tr>
<td>Blinding (performance bias and detection bias)</td>
<td>Low risk</td>
<td>The investigators and participants were blinded to the treatments</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>2 women were excluded (in 1 LS was not confirmed, and in the other the biopsy slide was lost)</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>The study protocol is available, and all of the prespecified outcomes have been reported</td>
</tr>
<tr>
<td>Degree of certainty that the participants have LS</td>
<td>Low risk</td>
<td>LS was proven by biopsy.</td>
</tr>
<tr>
<td>Baseline assessment of the participants</td>
<td>Unclear risk</td>
<td>This was not performed.</td>
</tr>
<tr>
<td>Drug identity, source, dose, duration of treatments, and adequacy of instructions</td>
<td>Low risk</td>
<td>The treatments were standardised.</td>
</tr>
</tbody>
</table>
Description and standardisation of outcome measures | Low risk | The outcome measures were described and standardised.
---|---|---
Discontinuation of previous treatments | Low risk | There was no use of systemic immunosuppressants or topical therapy within 4 weeks prior to participation in the trial.
Permission or standardisation of concomitant treatments | Unclear risk | There was no relevant description.
Use and appropriateness of statistical analyses where tabulated data could not be extracted from the original publication | Low risk | The trialists used correct statistical tests in their paper and provided us with further detailed data for analysis at our request.

**Kiss 2001**

Methods

This was a randomised controlled trial.

Participants

- 40 boys with penile lichen sclerosus

Interventions

A: mometasone furoate 0.05% ointment
B: placebo once daily
These were taken for 5 weeks.

Outcomes

Outcomes of the trial
1) Clinical score of phimosis

Notes

Setting: children's hospital
Country: Hungary
Funding source: not reported

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>There was no description of the process of randomisation.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>There was no description of the allocation concealment.</td>
</tr>
<tr>
<td>Blinding (performance bias and detection bias)</td>
<td>Unclear risk</td>
<td>There was no description of blinding.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>4 boys were lost to follow up - 3 in whom clinically suspected penile LS was not confirmed by pathological examination. There was no</td>
</tr>
</tbody>
</table>
**Selecte reporting (reporting bias)** | Low risk | A change in the clinical score of phimosis and adverse drug reactions was reported
---|---|---
**Degree of certainty that the participants have LS** | Low risk | All penile LS cases underwent circumcision, and those that could not be proven by biopsy were excluded
**Baseline assessment of the participants** | Unclear risk | This was not performed.
**Drug identity, source, dose, duration of treatments, and adequacy of instructions** | Low risk | The treatments were standardised.
**Description and standardisation of outcome measures** | Low risk | Phimosis was graded 1 to 4.
**Discontinuation of previous treatments** | Unclear risk | There was no relevant description.
**Permission or standardisation of concomitant treatments** | Unclear risk | There was no relevant description.
**Use and appropriateness of statistical analyses where tabulated data could not be extracted from the original publication** | Unclear risk | Student’s t-test was used to compare the scores before and after treatments, but Wilcoxon signed rank test should have been used

### Paslin 1991

**Methods**
This was a randomised cross-over trial.

**Participants**
- 5 women with biopsy-proven vulval LS

**Interventions**
A: dihydrotestosterone 2%
B: placebo (white petrolatum vehicle)
These were taken twice daily for 3 months, then treatment was reversed for another 3 months

**Outcomes**

**Outcomes of the trial**
1) Subjective symptoms
2) Objective gross improvement (documented by photographs)
3) Histopathological findings

**Notes**
Setting: private practice
Country: US
Funding source: not reported

**Risk of bias**
<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Randomisation was based on coin tossing.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Allocation could not be foreseen since randomisation was based on coin tossing by the office technician after the participants were enrolled</td>
</tr>
<tr>
<td>Blinding (performance bias and detection bias) All outcomes</td>
<td>Low risk</td>
<td>Neither the investigator nor the participants knew which medicine was being applied</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>There was no description of withdrawal or dropout.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Symptoms and objective gross improvement were assessed, but adverse drug reactions were not reported</td>
</tr>
<tr>
<td>Degree of certainty that the participants have LS</td>
<td>Low risk</td>
<td>LS was proven by biopsy.</td>
</tr>
<tr>
<td>Baseline assessment of the participants</td>
<td>Low risk</td>
<td>The participant was her own control since the study was a cross-over trial. All of the participants were middle- to old-aged women</td>
</tr>
<tr>
<td>Drug identity, source, dose, duration of treatments, and adequacy of instructions</td>
<td>Low risk</td>
<td>The treatments were standardised.</td>
</tr>
<tr>
<td>Description and standardisation of outcome measures</td>
<td>High risk</td>
<td>No grading system was used to assess the outcomes.</td>
</tr>
<tr>
<td>Discontinuation of previous treatments</td>
<td>High risk</td>
<td>All forms of treatment were withheld for at least 1 month before enrolment. The trial lacked a wash-out period, and a carry-over effect appeared in 2 out of 3 women who used dihydrotestosterone in the first 3-month segment of the trial</td>
</tr>
<tr>
<td>Permission or standardisation of concomitant treatments</td>
<td>Unclear risk</td>
<td>There was no relevant description.</td>
</tr>
<tr>
<td>Use and appropriateness of statistical analyses where tabulated data could not be extracted from the original publication</td>
<td>Low risk</td>
<td>We extracted tabulated data from the first period before cross-over</td>
</tr>
</tbody>
</table>
## Methods

This was a randomised cross-over trial.

## Participants

- 5 postmenopausal women with biopsy-proven vulval LS

## Interventions

- A: dihydrotestosterone 2%
- B: testosterone propionate 2%

These were taken twice daily for 3 months, then treatment was reversed for another 3 months

## Outcomes

**Outcomes of the trial**

1. Vulval itching (0 to 4 scale)
2. Dyspareunia (presence or absence)
3. Gross appearance (photographic improvement)
4. Histopathological findings (formation of elastic fibres)

## Notes

- Setting: university hospital
- Country: US
- Funding source: not reported

## Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Randomisation was based on coin tossing.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Allocation could not be foreseen since randomisation was based on coin tossing by the office technician after the participants were enrolled</td>
</tr>
<tr>
<td>Blinding (performance bias and detection bias) All outcomes</td>
<td>Low risk</td>
<td>Neither the investigator nor the participants knew which androgen was being applied</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>There was no description of withdrawal or dropout.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Itching, dyspareunia, and objective gross improvement were assessed, but pain and adverse drug reactions were not reported</td>
</tr>
<tr>
<td>Degree of certainty that the participants have LS</td>
<td>Low risk</td>
<td>LS was proven by biopsy.</td>
</tr>
<tr>
<td>Baseline assessment of the participants</td>
<td>Low risk</td>
<td>The participant was her own control since the study was a cross-over trial. All of the participants were middle- to old-aged women</td>
</tr>
</tbody>
</table>
### Paslin 1996

| Drug identity, source, dose, duration of treatments, and adequacy of instructions | Low risk | The treatments were standardised. |
| Description and standardisation of outcome measures | High risk | Only 1 outcome measure, vulval itching, was standardised at planning, but no rating was reported. No grading system was used for other outcome measures |
| Discontinuation of previous treatments | High risk | For at least 1 month before enrolment, the participants were allowed to use pramozine hydrochloride gel, cold compresses, and/or plain white petrolatum, but no androgens or corticosteroids were applied. However, the trial lacked a wash-out period |
| Permission or standardisation of concomitant treatments | Unclear risk | There was no relevant description. |
| Use and appropriateness of statistical analyses where tabulated data could not be extracted from the original publication | Low risk | We extracted tabulated data from the first period before cross-over |

### Sideri 1994

| Methods | This was a randomised controlled trial. |
| Participants | • 58 women with histologically confirmed vulval LS |
| Interventions | A: testosterone propionate 2%  
B: placebo (petrolatum ointment)  
These were taken for 1 year. |
| Outcomes | **Outcomes of the trial**  
1) Symptoms  
2) Gross appearance  
3) Histological changes |
| Notes | Setting: university hospital  
Country: Italy  
Funding source: not reported |

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>There was no description of the process of randomisation.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>There was no description of the allocation concealment.</td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>--------------</td>
<td>---------------------------------------------------------</td>
</tr>
<tr>
<td>Blinding (performance bias and detection bias)</td>
<td>Low risk</td>
<td>Neither the investigator nor the participants knew which medicine was being applied</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>There was no description of withdrawal or dropout.</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Improvement in symptoms, gross appearance, and adverse drug reactions were reported</td>
</tr>
<tr>
<td>Degree of certainty that the participants have LS</td>
<td>Low risk</td>
<td>LS was proven by biopsy.</td>
</tr>
<tr>
<td>Baseline assessment of the participants</td>
<td>Unclear risk</td>
<td>This was not performed.</td>
</tr>
<tr>
<td>Drug identity, source, dose, duration of treatments, and adequacy of instructions</td>
<td>Low risk</td>
<td>The treatments were standardised.</td>
</tr>
<tr>
<td>Description and standardisation of outcome measures</td>
<td>Unclear risk</td>
<td>Although a scoring system was used to assess clinical and symptomatic status, no relevant details were provided</td>
</tr>
<tr>
<td>Discontinuation of previous treatments</td>
<td>Low risk</td>
<td>All participants received an initial 2-week course of topical antibiotic-corticosteroid cream before allocation, then they were randomised to the testosterone and placebo groups</td>
</tr>
<tr>
<td>Permission or standardisation of concomitant treatments</td>
<td>Unclear risk</td>
<td>There was no relevant description.</td>
</tr>
<tr>
<td>Use and appropriateness of statistical analyses where tabulated data could not be extracted from the original publication</td>
<td>Low risk</td>
<td>We extracted tabulated data from the trial.</td>
</tr>
</tbody>
</table>

VAS= visual analogue scale
PR=pruritus
BP= burning/pain
### Characteristics of excluded studies  
[ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chari 1994</td>
<td>This was a case series.</td>
</tr>
<tr>
<td>Diakomanolis 2002</td>
<td>Randomisation was not mentioned (this was a retrospective cohort study)</td>
</tr>
<tr>
<td>Friedrich 1971</td>
<td>Randomisation was not mentioned (this was a controlled study)</td>
</tr>
<tr>
<td>Li 2004</td>
<td>This was a phase 2 study, not a RCT.</td>
</tr>
<tr>
<td>Origoni 1996</td>
<td>Randomisation was not mentioned (this was a controlled study)</td>
</tr>
<tr>
<td>Skierlo 1987</td>
<td>This was a case series.</td>
</tr>
<tr>
<td>Sotiriou 2008</td>
<td>This was a case series.</td>
</tr>
<tr>
<td>Zarcone 1996</td>
<td>Randomisation was not mentioned (this was a retrospective cohort study)</td>
</tr>
<tr>
<td>Zhu 2006</td>
<td>This was not a RCT according to the Chinese content of the paper</td>
</tr>
</tbody>
</table>

### Characteristics of ongoing studies  
[ordered by study ID]

**NCT00757874**

<table>
<thead>
<tr>
<th>Trial name or title</th>
<th>A Double Blind Phase II Study Comparing Safety and Efficacy of Tacrolimus Versus Topical Clobetasol Propionate in the Treatment of Vulvar Lichen Sclerosus</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>This is a RCT.</td>
</tr>
</tbody>
</table>
| Participants        | **Inclusion criteria of the trial**  
|                     | • Women with vulval LS                                                                                                                        |
| Interventions       | A: tacrolimus cream  
|                     | B: clobetasol propionate  
|                     | These were taken for 3 months.                                                                                                               |
| Outcomes            | **Primary outcomes of the trial**  
|                     | 1) Efficacy assessed by medical examinations and reporting of symptoms  
|                     | **Secondary outcomes of the trial**  
|                     | 1) Presence and severity of side-effects                                                                                                     |
| Starting date       | April 2006                                                                                                                                   |
| Contact information | Dr Deana Funaro (rouleaufunaro@videotron.ca)                                                                                                 |
| Notes               | -                                                                                                                                             |
### NCT01126255

**Trial name or title**
Efficacy of a Topical Therapy With Progesterone Compared to the Conventional Therapy With Clobetasol Propionate in Patients With Vulvar Lichen Sclerosus. A Double Blind, Randomized Phase II Pilot Study

**Methods**
This is a RCT.

**Participants**
**Inclusion criteria of the trial**
- Women aged at least 18 years with vulvar LS

**Interventions**
A: clobetasol propionate 0.05%
B: progesterone 8%
These topical applications were taken once daily for 12 weeks

**Outcomes**
- **Primary outcomes of the trial**
  1) Score of the characteristics of LS based on vulvar efflorescences
- **Secondary outcomes of the trial**
  1) Patient-reported symptom
  2) Quality of life
  3) Adverse events

**Starting date**
June 2011

**Contact information**
Dr Andreas Guenthert (andreas.guenthert@insel.ch)
Professor Michel Mueller (michel.mueller@insel.ch)

**Notes**
-

### NCT01400022

**Trial name or title**
A Randomized Clinical Study Comparing Topical 0.05% Clobetasol Propionate in Vaseline With UVA-1 Phototherapy in the Treatment of Vulvar Lichen Sclerosus

**Methods**
This is a RCT.

**Participants**
**Inclusion criteria of the trial**
- Women aged over 18 years with vulvar LS

**Interventions**
A: UVA1-phototherapy 4 times per week
B: clobetasol propionate (0.05%) in white Vaseline applied thinly once daily over a period of 3 months

**Outcomes**
- **Primary outcomes of the trial**
  1) Clinical improvement during UVA1/cortisone treatment
- **Secondary outcomes of the trial**
  1) Subjective patient score
  2) Influence on quality of life
  3) Colorimetry
  4) Ultrasound to determine the severity of the sclerosis
  5) Immunological, RT-PCR, and histological parameters in skin biopsies
**NCT01400022 (Continued)**

<table>
<thead>
<tr>
<th>Starting date</th>
<th>August 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact information</td>
<td>Dr Sarah Terras (<a href="mailto:s.terras@klinikum-bochum.de">s.terras@klinikum-bochum.de</a>)</td>
</tr>
<tr>
<td>Notes</td>
<td>-</td>
</tr>
</tbody>
</table>
### DATA AND ANALYSES

#### Comparison 1. Clobetasol vs placebo

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Participant-rated improvement or remission of symptoms</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2 Investigator-rated global degree of improvement</td>
<td>1</td>
<td></td>
<td>Std. Mean Difference (IV, Random, 95% CI)</td>
<td>Totals not selected</td>
</tr>
</tbody>
</table>

#### Comparison 2. Mometasone vs placebo

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Investigator-rated change in clinical score of phimosis from baseline</td>
<td>1</td>
<td></td>
<td>Std. Mean Difference (IV, Random, 95% CI)</td>
<td>Totals not selected</td>
</tr>
</tbody>
</table>

#### Comparison 3. Testosterone vs placebo

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Participant-rated improvement or remission of symptoms</td>
<td>2</td>
<td>97</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>1.21 [0.56, 2.64]</td>
</tr>
<tr>
<td>2 Investigator-rated improvement of gross appearance</td>
<td>1</td>
<td></td>
<td>Std. Mean Difference (IV, Random, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>3 Adverse drug reactions that were severe enough to require withdrawal of treatment</td>
<td>2</td>
<td>97</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>5.19 [0.62, 43.19]</td>
</tr>
</tbody>
</table>
### Comparison 4. Dihydrotestosterone vs placebo

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Investigator-rated gross improvement</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>Totals not selected</td>
</tr>
</tbody>
</table>

### Comparison 5. Testosterone vs clobetasol

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Participant-rated improvement or remission of symptoms</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2 Investigator-rated global degree of improvement</td>
<td>1</td>
<td></td>
<td>Std. Mean Difference (IV, Random, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>3 Adverse drug reactions that were severe enough to require withdrawal of treatment</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>4 Adverse drug reactions that were not severe enough to require cessation of treatment</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>Totals not selected</td>
</tr>
</tbody>
</table>

### Comparison 6. Testosterone vs dihydrotestosterone

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Participant-rated remission of itching</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2 Investigator-rated gross improvement</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>Totals not selected</td>
</tr>
</tbody>
</table>
### Comparison 7. Testosterone vs placebo as maintenance therapy

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Participant-rated global degree of improvement</td>
<td></td>
<td>Other data</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2 Investigator-rated global degree of improvement</td>
<td></td>
<td>Other data</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>3 Adverse drug reactions that were severe enough to require cessation of treatment</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>Totals not selected</td>
</tr>
</tbody>
</table>

### Comparison 8. Progesterone vs placebo

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Participant-rated improvement or remission of symptoms</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2 Investigator-rated global degree of improvement</td>
<td>1</td>
<td></td>
<td>Std. Mean Difference (IV, Random, 95% CI)</td>
<td>Totals not selected</td>
</tr>
</tbody>
</table>

### Comparison 9. Pimecrolimus vs clobetasol

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Change in pruritus (VAS-PR)</td>
<td>1</td>
<td></td>
<td>Std. Mean Difference (IV, Random, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2 Change in burning/pain (VAS-BP)</td>
<td>1</td>
<td></td>
<td>Std. Mean Difference (IV, Random, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>3 Investigator-rated global degree of improvement</td>
<td>1</td>
<td></td>
<td>Std. Mean Difference (IV, Random, 95% CI)</td>
<td>Totals not selected</td>
</tr>
</tbody>
</table>
Analysis 1.1. Comparison 1 Clobetasol vs placebo, Outcome 1 Participant-rated improvement or remission of symptoms.

Review: Topical interventions for genital lichen sclerosus

Comparison: 1 Clobetasol vs placebo

Outcome: 1 Participant-rated improvement or remission of symptoms

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Clobetasol</th>
<th>Placebo</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H,Random,95% CI</td>
<td>M-H,Random,95% CI</td>
</tr>
<tr>
<td>Bracco 1993</td>
<td>18/20</td>
<td>6/19</td>
<td>2.85 [ 1.45, 5.61 ]</td>
<td></td>
</tr>
</tbody>
</table>

Favours placebo Favours clobetasol

Analysis 1.2. Comparison 1 Clobetasol vs placebo, Outcome 2 Investigator-rated global degree of improvement.

Review: Topical interventions for genital lichen sclerosus

Comparison: 1 Clobetasol vs placebo

Outcome: 2 Investigator-rated global degree of improvement

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Clobetasol</th>
<th>Placebo</th>
<th>Std. Mean Difference</th>
<th>Std. Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N Mean(SD)</td>
<td>N Mean(SD)</td>
<td>IV,Random,95% CI</td>
<td>IV,Random,95% CI</td>
</tr>
<tr>
<td>Bracco 1993 (1)</td>
<td>20 3.9 (0.52)</td>
<td>19 0.3 (0.7)</td>
<td>5.74 [ 4.26, 7.23 ]</td>
<td></td>
</tr>
</tbody>
</table>

(1) The SDs were calculated based on the data provided in the paper.
Analysis 2.1. Comparison 2 Mometasone vs placebo, Outcome 1 Investigator-rated change in clinical score of phimosis from baseline.

Review: Topical interventions for genital lichen sclerosus
Comparison: 2 Mometasone vs placebo
Outcome: 1 Investigator-rated change in clinical score of phimosis from baseline

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Mometasone</th>
<th>Placebo</th>
<th>Std. Mean Difference IV,Random,95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td></td>
</tr>
<tr>
<td>Kiss 2001</td>
<td>17</td>
<td>-0.41 (0.68)</td>
<td>-1.04 [ -1.77, -0.31 ]</td>
</tr>
</tbody>
</table>

Analysis 3.1. Comparison 3 Testosterone vs placebo, Outcome 1 Participant-rated improvement or remission of symptoms.

Review: Topical interventions for genital lichen sclerosus
Comparison: 3 Testosterone vs placebo
Outcome: 1 Participant-rated improvement or remission of symptoms

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Testosterone</th>
<th>Placebo</th>
<th>Risk Ratio M-H,Random,95% CI</th>
<th>Weight</th>
<th>Risk Ratio M-H,Random,95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bracco 1993</td>
<td>12/20</td>
<td>6/19</td>
<td>4.09 [ 0.90, 4.03 ]</td>
<td>40.9 %</td>
<td></td>
</tr>
<tr>
<td>Sideri 1994</td>
<td>20/30</td>
<td>21/28</td>
<td>0.89 [ 0.64, 1.24 ]</td>
<td>59.1 %</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>50</strong></td>
<td><strong>47</strong></td>
<td><strong>100.0 %</strong></td>
<td><strong>1.21 [ 0.56, 2.64 ]</strong></td>
<td></td>
</tr>
</tbody>
</table>
**Analysis 3.2.** Comparison 3 Testosterone vs placebo, Outcome 2 Investigator-rated improvement of gross appearance.

Review: Topical interventions for genital lichen sclerosus

Comparison: 3 Testosterone vs placebo

Outcome: 2 Investigator-rated improvement of gross appearance

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Testosterone</th>
<th>Placebo</th>
<th>Std. Mean Difference</th>
<th>Std. Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N  Mean(SD)</td>
<td>N  Mean(SD)</td>
<td>IV,Random,95% CI</td>
<td>IV,Random,95% CI</td>
</tr>
<tr>
<td>Bracco 1993</td>
<td>20 1 (2.16)</td>
<td>19 0.3 (0.7)</td>
<td>0.42 [-0.21, 1.06]</td>
<td></td>
</tr>
<tr>
<td>Sideri 1994</td>
<td>1/30 0/28</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>50 47</td>
<td></td>
<td></td>
<td>5.19 [0.62, 43.19]</td>
</tr>
</tbody>
</table>

Heterogeneity: Tau² = 0.0; Chi² = 0.27; df = 1 (P = 0.60); I² = 0.0%

Test for overall effect: Z = 1.52 (P = 0.13)

Test for subgroup differences: Not applicable

**Analysis 3.3.** Comparison 3 Testosterone vs placebo, Outcome 3 Adverse drug reactions that were severe enough to require withdrawal of treatment.

Review: Topical interventions for genital lichen sclerosus

Comparison: 3 Testosterone vs placebo

Outcome: 3 Adverse drug reactions that were severe enough to require withdrawal of treatment

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Testosterone</th>
<th>Placebo</th>
<th>Risk Ratio</th>
<th>Weight</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H,Random,95% CI</td>
<td></td>
<td>M-H,Random,95% CI</td>
</tr>
<tr>
<td>Bracco 1993</td>
<td>4/20</td>
<td>0/19</td>
<td>55.0 % 8.57 [0.49, 149.20]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sideri 1994</td>
<td>1/30</td>
<td>0/28</td>
<td>45.0 % 2.81 [0.12, 66.17]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>50 47</td>
<td></td>
<td>100.0 % 5.19 [0.62, 43.19]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total events: 5 (Testosterone), 0 (Placebo)

Heterogeneity: Tau² = 0.0; Chi² = 1.52; df = 1 (P = 0.21); I² = 0.0%

Test for overall effect: Z = 1.52 (P = 0.13)

Test for subgroup differences: Not applicable
### Analysis 4.1. Comparison 4 Dihydrotestosterone vs placebo, Outcome 1 Investigator-rated gross improvement.

Review: Topical interventions for genital lichen sclerosis  
Comparison: 4 Dihydrotestosterone vs placebo  
Outcome: 1 Investigator-rated gross improvement

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Dihydrotestosterone n/N</th>
<th>Placebo n/N</th>
<th>Risk Ratio M-H,Random,95% CI</th>
<th>Risk Ratio M-H,Random,95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paslin 1991</td>
<td>3/3</td>
<td>0/2</td>
<td>5.25 [0.41, 67.73]</td>
<td></td>
</tr>
</tbody>
</table>

Favours dihydrotestosterone

### Analysis 5.1. Comparison 5 Testosterone vs clobetasol, Outcome 1 Participant-rated improvement or remission of symptoms.

Review: Topical interventions for genital lichen sclerosis  
Comparison: 5 Testosterone vs clobetasol  
Outcome: 1 Participant-rated improvement or remission of symptoms

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Testosterone n/N</th>
<th>Clobetasol n/N</th>
<th>Risk Ratio M-H,Random,95% CI</th>
<th>Risk Ratio M-H,Random,95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bracco 1993</td>
<td>12/20</td>
<td>18/20</td>
<td>0.67 [0.45, 0.98]</td>
<td></td>
</tr>
</tbody>
</table>

Favours clobetasol

---

Topical interventions for genital lichen sclerosus (Review)  
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Analysis 5.2. Comparison 5 Testosterone vs clobetasol, Outcome 2 Investigator-rated global degree of improvement.

**Review:** Topical interventions for genital lichen sclerosus  
**Comparison:** 5 Testosterone vs clobetasol  
**Outcome:** 2 Investigator-rated global degree of improvement

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Testosterone</th>
<th>Clobetasol</th>
<th>Std. Mean Difference</th>
<th>Std. Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N Mean(SD)</td>
<td>N Mean(SD)</td>
<td>IV,Random,95% CI</td>
<td>IV,Random,95% CI</td>
</tr>
<tr>
<td>Bracco 1993 (1)</td>
<td>20 1 (2.16)</td>
<td>20 3.9 (0.52)</td>
<td>-1.81 [-2.56, -1.06]</td>
<td></td>
</tr>
</tbody>
</table>

(1) The SDs were calculated based on the data provided in the paper.

### Analysis 5.3. Comparison 5 Testosterone vs clobetasol, Outcome 3 Adverse drug reactions that were severe enough to require withdrawal of treatment.

**Review:** Topical interventions for genital lichen sclerosus  
**Comparison:** 5 Testosterone vs clobetasol  
**Outcome:** 3 Adverse drug reactions that were severe enough to require withdrawal of treatment

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Testosterone</th>
<th>Clobetasol</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H,Random,95% CI</td>
<td>M-H,Random,95% CI</td>
</tr>
<tr>
<td>Bracco 1993</td>
<td>1/20</td>
<td>0/20</td>
<td>3.00 [0.13, 69.52]</td>
<td></td>
</tr>
</tbody>
</table>

0.01 0.1 1 10 100  
Favours testosterone  
Favours clobetasol
### Analysis 5.4. Comparison 5 Testosterone vs clobetasol, Outcome 4 Adverse drug reactions that were not severe enough to require cessation of treatment.

**Review:** Topical interventions for genital lichen sclerosis  
**Comparison:** 5 Testosterone vs clobetasol  
**Outcome:** 4 Adverse drug reactions that were not severe enough to require cessation of treatment

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Testosterone n/N</th>
<th>Clobetasol n/N</th>
<th>Risk Ratio M-H,Random,95% CI</th>
<th>Risk Ratio M-H,Random,95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bracco 1993</td>
<td>3/20</td>
<td>0/20</td>
<td>7.00 [ 0.38, 127.32 ]</td>
<td>0.01 0.1 1 10 100</td>
</tr>
</tbody>
</table>

Favours testosterone  
Favours clobetasol

### Analysis 6.1. Comparison 6 Testosterone vs dihydrotestosterone, Outcome 1 Participant-rated remission of itching.

**Review:** Topical interventions for genital lichen sclerosis  
**Comparison:** 6 Testosterone vs dihydrotestosterone  
**Outcome:** 1 Participant-rated remission of itching

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Testosterone n/N</th>
<th>Dihydrotestosterone n/N</th>
<th>Risk Ratio M-H,Random,95% CI</th>
<th>Risk Ratio M-H,Random,95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paslin 1996</td>
<td>0/3</td>
<td>1/2</td>
<td>0.25 [ 0.01, 4.23 ]</td>
<td>0.01 0.1 1 10 100</td>
</tr>
</tbody>
</table>

Favours dihydrotestosterone  
Favours testosterone
Analysis 6.2. Comparison 6 Testosterone vs dihydrotestosterone, Outcome 2 Investigator-rated gross improvement.

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Testosterone n/N</th>
<th>Dihydrotestosterone n/N</th>
<th>Risk Ratio M-H,Random,95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paslin 1996</td>
<td>3/3</td>
<td>2/2</td>
<td>1.00 [0.53, 1.87]</td>
</tr>
</tbody>
</table>

Analysis 7.1. Comparison 7 Testosterone vs placebo as maintenance therapy, Outcome 1 Participant-rated global degree of improvement.

<table>
<thead>
<tr>
<th>Study</th>
<th>Testosterone</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cattaneo 1996</td>
<td>The symptom score significantly worsened from 6 to 23 (p &lt; 0.05)</td>
<td>No significant change in the symptom score.</td>
</tr>
</tbody>
</table>

Analysis 7.2. Comparison 7 Testosterone vs placebo as maintenance therapy, Outcome 2 Investigator-rated global degree of improvement.

<table>
<thead>
<tr>
<th>Study</th>
<th>Testosterone</th>
<th>Placebo</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cattaneo 1996</td>
<td>No significant change in the score of gross appearance.</td>
<td>No significant change in the score of gross appearance.</td>
<td></td>
</tr>
</tbody>
</table>
### Analysis 7.3. Comparison 7 Testosterone vs placebo as maintenance therapy, Outcome 3 Adverse drug reactions that were severe enough to require cessation of treatment.

Review: Topical interventions for genital lichen sclerosus
Comparison: 7 Testosterone vs placebo as maintenance therapy
Outcome: 3 Adverse drug reactions that were severe enough to require cessation of treatment

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Testosterone</th>
<th>Placebo</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H,Random,95% CI</td>
<td>M-H,Random,95% CI</td>
</tr>
<tr>
<td>Cattaneo 1996</td>
<td>4/16</td>
<td>0/16</td>
<td>9.00 [ 0.52, 154.56 ]</td>
<td></td>
</tr>
</tbody>
</table>

- 0.01 0.1 1 10 100
- Favours testosterone Favours placebo

### Analysis 8.1. Comparison 8 Progesterone vs placebo, Outcome 1 Participant-rated improvement or remission of symptoms.

Review: Topical interventions for genital lichen sclerosus
Comparison: 8 Progesterone vs placebo
Outcome: 1 Participant-rated improvement or remission of symptoms

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Progesterone</th>
<th>Placebo</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H,Random,95% CI</td>
<td>M-H,Random,95% CI</td>
</tr>
<tr>
<td>Bracco 1993</td>
<td>10/20</td>
<td>6/19</td>
<td>1.58 [ 0.72, 3.50 ]</td>
<td></td>
</tr>
</tbody>
</table>

- 0.01 0.1 1 10 100
- Favours placebo Favours progesterone
### Analysis 8.2. Comparison 8 Progesterone vs placebo, Outcome 2 Investigator-rated global degree of improvement.

**Review:** Topical interventions for genital lichen sclerosus  
**Comparison:** 8 Progesterone vs placebo  
**Outcome:** 2 Investigator-rated global degree of improvement

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Progesterone</th>
<th>Placebo</th>
<th>Std. Mean Difference</th>
<th>Std. Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>Bracco 1993 (1)</td>
<td>20</td>
<td>1.1 (3.15)</td>
<td>19</td>
<td>0.3 (0.7)</td>
</tr>
</tbody>
</table>

(1) The SDs were calculated based on the data provided in the paper.

---

### Analysis 9.1. Comparison 9 Pimecrolimus vs clobetasol, Outcome 1 Change in pruritus (VAS-PR).

**Review:** Topical interventions for genital lichen sclerosus  
**Comparison:** 9 Pimecrolimus vs clobetasol  
**Outcome:** 1 Change in pruritus (VAS-PR)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Pimecrolimus</th>
<th>Clobetasol</th>
<th>Std. Mean Difference</th>
<th>Std. Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>Goldstein 2011</td>
<td>17</td>
<td>3.5 (3.2)</td>
<td>19</td>
<td>4.5 (2.8)</td>
</tr>
</tbody>
</table>

---
### Analysis 9.2. Comparison 9 Pimecrolimus vs clobetasol, Outcome 2 Change in burning/pain (VAS-BP).

**Review:** Topical interventions for genital lichen sclerosus  
**Comparison:** 9 Pimecrolimus vs clobetasol  
**Outcome:** 2 Change in burning/pain (VAS-BP)

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Pimecrolimus</th>
<th>Clobetasol</th>
<th>Std. Mean Difference</th>
<th>Std. Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N Mean(SD)</td>
<td>N Mean(SD)</td>
<td>IV,Random,95% CI</td>
<td>IV,Random,95% CI</td>
</tr>
<tr>
<td>Goldstein 2011</td>
<td>17 3.8 (2.9)</td>
<td>19 3.7 (2.8)</td>
<td>0.03 [-0.62, 0.69]</td>
<td></td>
</tr>
</tbody>
</table>

Favours clobetasol  
Favours pimecrolimus

### Analysis 9.3. Comparison 9 Pimecrolimus vs clobetasol, Outcome 3 Investigator-rated global degree of improvement.

**Review:** Topical interventions for genital lichen sclerosus  
**Comparison:** 9 Pimecrolimus vs clobetasol  
**Outcome:** 3 Investigator-rated global degree of improvement

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Pimecrolimus</th>
<th>Clobetasol</th>
<th>Std. Mean Difference</th>
<th>Std. Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N Mean(SD)</td>
<td>N Mean(SD)</td>
<td>IV,Random,95% CI</td>
<td>IV,Random,95% CI</td>
</tr>
<tr>
<td>Goldstein 2011</td>
<td>17 1.2 (0.9)</td>
<td>19 2.4 (0.5)</td>
<td>-1.64 [-2.40, -0.87]</td>
<td></td>
</tr>
</tbody>
</table>

Favours clobetasol  
Favours pimecrolimus

### ADDITIONAL TABLES

**Table 1. Potency of topical corticosteroids (as defined by the British National Formulary)**

<table>
<thead>
<tr>
<th>Potency</th>
<th>Topical corticosteroids</th>
</tr>
</thead>
</table>
| Mild        | Hydrocortisone 0.1% to 2.5%  
Fluocinolone acetonide 0.00625%                                                       |
| Moderate    | Alclometasone dipropionate 0.05%  
Betamethasone valerate 0.025%  
Clobetasone butyrate 0.05%  
Fludrocortisone (flurandrenolone) 0.0125%                                              |

---

Topical interventions for genital lichen sclerosus (Review)  
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Potency of topical corticosteroids (as defined by the British National Formulary) (Continued)

<table>
<thead>
<tr>
<th>Potency</th>
<th>Topical Corticosteroids</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flucortolone 0.25%</td>
<td></td>
</tr>
<tr>
<td>Potent</td>
<td></td>
</tr>
<tr>
<td>Betamethasone dipropionate 0.05% to 0.064%</td>
<td></td>
</tr>
<tr>
<td>Betamethasone valerate 0.1% to 0.12%</td>
<td></td>
</tr>
<tr>
<td>Diflucortolone valerate 0.1%</td>
<td></td>
</tr>
<tr>
<td>Fluocinolone acetonide 0.025%</td>
<td></td>
</tr>
<tr>
<td>Fluocinonide 0.05%</td>
<td></td>
</tr>
<tr>
<td>Fluticasone propionate 0.005% to 0.05%</td>
<td></td>
</tr>
<tr>
<td>Hydrocortisone butyrate 0.1%</td>
<td></td>
</tr>
<tr>
<td>Mometasone furoate 0.1%</td>
<td></td>
</tr>
<tr>
<td>Triamcinolone acetonide 0.1%</td>
<td></td>
</tr>
<tr>
<td>Very potent</td>
<td></td>
</tr>
<tr>
<td>Clobetasol propionate 0.05%</td>
<td></td>
</tr>
<tr>
<td>Diflucortolone valerate 0.3%</td>
<td></td>
</tr>
</tbody>
</table>

A P P E N D I C E S

Appendix 1. CENTRAL (Cochrane Library) search strategy

#1(lichen and (sclerosus or atrophi* or albus or scleureux or sclero-atrophi* or vulva*))
#2(balanitis and (xerotica or obliteran* or sclerotica))
#3(vulva* and dystroph*) or (white and spot and disease*)
#4MeSH descriptor Lichen Sclerosus et Atrophicus explode all trees
#5MeSH descriptor Vulvar Lichen Sclerosus explode all trees
#6MeSH descriptor Balanitis explode all trees
#7(#1 OR #2 OR #3 OR #4 OR #5 OR #6)
#8(SR-SKIN)
#9(#7 AND NOT #8)

Appendix 2. MEDLINE (OVID) search strategy

1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. clinical trials as topic.sh.
6. randomly.ab.
7. trial.ti.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. (animals not (human and animals)).sh.
10. 8 not 9
11. lichen sclerosus.mp. or exp Lichen Sclerosus et Atrophicus/
12. (kraurosis vulvae or kraurosis vulva).mp. or exp Vulvar Lichen Sclerosus/
13. lichen albus.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
14. exp Balanitis Xerotica Obliterans/ or exp Balanitis/ or balanitis.mp.
15. kraurosis penis.mp.
16. balanitis sclerotica obliterans.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
17. balanitis sclerotica.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
18. white spot disease.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
19. sclero-atrophic lichen.mp.
20. lichen sclero-atrophique.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
21. vulval dystrophy.mp.
22. 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
23. 23 and 10

Appendix 3. EMBASE (OVID) search strategy

1. random$.mp.
2. factorial$.mp.
3. (crossover$ or cross-over$).mp.
4. placebo$.mp. or PLACEBO/
5. (doub$ adj blind$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]
6. (singl$ adj blind$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]
7. (assign$ or allocat$).mp.
8. volunteer$.mp. or VOLUNTEER/
9. Crossover Procedure/
10. Double Blind Procedure/
11. Randomized Controlled Trial/
12. Single Blind Procedure/
13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
14. lichen sclerosus.mp. or exp Lichen Sclerosus et Atrophicus/
15. (kraurosis vulvae or kraurosis vulva).mp. or exp Vulvar Lichen Sclerosus/
16. lichen albus.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]
17. exp Balanitis Xerotica Obliterans/ or exp Balanitis/ or balanitis.mp.
18. kraurosis penis.mp.
19. balanitis sclerotica obliterans.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]
20. balanitis sclerotica.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]
21. white spot disease.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]
22. sclero-atrophic lichen.mp.
23. lichen sclero-atrophique.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]
24. vulval dystrophy.mp.
25. 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25
26. 13 and 26
Appendix 4. LILACS search strategy

((Pt RANDOMIZED CONTROLLED TRIAL OR Pt CONTROLLED CLINICAL TRIAL OR Mh RANDOMIZED CONTROLLED TRIALS OR Mh RANDOM ALLOCATION OR Mh DOUBLE-BLIND METHOD OR Mh SINGLE-BLIND METHOD OR Pt MULTICENTER STUDY) OR ((tw ensaio or tw ensayo or tw trial) and (tw azar or tw acaso or tw placebo or tw control$ or tw aleat$ or tw random$ or (tw duplo and tw cego) or (tw doble and tw ciego) or (tw double and tw blind)) and tw clinic$)) AND NOT ((CT ANIMALS OR MH ANIMALS OR CT RABBITS OR CT MICE OR MH RATS OR MH PRIMATES OR MH DOGS OR MH RABBITS OR MH SWINE) AND NOT (CT HUMAN AND CT ANIMALS)) [Words] and (lichen or liquen) or balanitis or (krausosis or craurosis) or vulva$ [Words]

Appendix 5. CINAHL search strategy

(PT Clinical trial OR PT Drugs OR AB randomi?ed OR AB placebo OR AB randomly OR TI trial) AND (lichen sclerosus OR kraurosis vulvae OR kraurosis vulva OR vulvar lichen sclerosis OR lichen albus OR balanitis xerotica obliteratorans OR balanitis OR kraurosis penis OR balanitis sclerotica obliteratorans OR balanitis sclerotica OR white spot disease OR sclero-atrophic lichen OR lichen sclero-atrophique OR vulval dystrophy)

Appendix 6. BNIA search strategy

1. randomi#ed controlled trial.mp.
2. controlled clinical trial.mp.
3. randomi#ed.ab.
4. placebo.ab.
5. clinical trial.mp.
6. randomly.ab.
7. trial.ti.
8. 1 or 2 or 3 or 4 or 5 or 6 or 7
9. lichen sclerosis.mp.
10. (kraurosis vulvae or kraurosis vulva).mp.
11. lichen albus.mp.
12. balanitis.mp.
13. kraurosis penis.mp.
14. balanitis sclerotica obliteratorans.mp.
15. balanitis sclerotica.mp.
16. white spot disease.mp.
17. sclero-atrophic lichen.mp.
18. lichen sclero-atrophique.mp.
19. vulval dystrophy.mp.
20. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20
21. 8 and 21
Appendix 7. SCI-EXPANDED, BIOSIS Previews, and CPCI-S search strategy

#1 TS=(randomi*ed controlled trial)
#2 TS=(controlled clinical trial)
#3 TS=(randomi*ed)
#4 TS=(placebo)
#5 TS=(clinical trial)
#6 TS=(randomly)
#7 TI=(trial)
#8 #7 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#9 TS=(lichen sclerosus)
#10 TS=(kraurosis vulvae OR kraurosis vulva)
#11 TS=(lichen albus)
#12 TS=(balanitis)
#13 TS=(kraurosis penis)
#14 TS=(balanitis sclerotica obliterans)
#15 TS=(balanitis sclerotica)
#16 TS=(white spot disease)
#17 TS=(sclero-atrophic lichen)
#18 TS=(lichen sclero-leveux)
#19 TS=(lichen sclero-atrophique)
#20 TS=(vulval dystrophy)
#21 #20 OR #19 OR #18 OR #17 OR #16 OR #15 OR #14 OR #13 OR #12 OR #11 OR #10 OR #9
#22 #8 AND #21

Appendix 8. Trials registers search strategy

lichen sclerosus OR kraurosis vulvae OR kraurosis vulva OR lichen albus OR balanitis xerotica obliterans OR balanitis OR kraurosis penis OR balanitis sclerotica obliterans OR balanitis sclerotica OR white spot disease OR sclero-atrophic lichen OR lichen sclero-leveux OR lichen sclero-atrophique OR vulval dystrophy

Appendix 9. Conference Papers Index search strategy

(KW=(randomi*ed controlled trial OR controlled clinical trial OR randomi*ed OR placebo OR clinical trial OR randomly) OR (TI=trial)) AND (KW=lichen sclerosus OR kraurosis vulvae OR kraurosis vulva OR lichen albus OR balanitis xerotica obliterans OR balanitis OR kraurosis penis OR balanitis sclerotica obliterans OR balanitis sclerotica OR white spot disease OR sclero-atrophic lichen OR lichen sclero-leveux OR lichen sclero-atrophique OR vulval dystrophy)

HISTORY

Protocol first published: Issue 1, 2010

Review first published: Issue 12, 2011
CONTRIBUTIONS OF AUTHORS

Link with the editorial base and co-ordinating contributions from co-authors - CC
Drafting the protocol - CC, MB, GK, FW, FL, and FB
Dialogue with the Trials Search Co-ordinator - CC
Identifying relevant titles and abstracts from the searches - CC and GK
Obtaining copies of the trials - CC
Selecting the trials - CC and GK
Extracting the data - CC and GK
Entering the data into RevMan - CC
Carrying out the analysis - CC and GK
Interpreting the data - CC, GK, and FW
Drafting the final review - CC with contribution from all
Updating the review - CC

DECLARATIONS OF INTEREST

None known.

SOURCES OF SUPPORT

Internal sources

• Vrije Universiteit Medisch Centrum, Netherlands.
• St John’s Institute of Dermatology, UK.

External sources

• British Society for the Study of Vulval Disease, UK.
  Funding
• Chang Gung Memorial Hospital-Chiayi (CMRPG690041), Taiwan.
  Funding
D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W

After discussion with our consumer author (FB), we made amendments in the Background to stress that lichen sclerosus can affect the quality of the sex lives of people with this condition, including painful sex and less pleasurable sex. This issue is under-investigated, and in the Implications for research we encourage researchers to examine this aspect in future trials.

We revised the Description of the intervention to describe what the treatments are, how they work, and their side-effects.

We have updated some references in the Background text.

In the protocol, we prespecified the first primary outcome as ‘participant-rated global degree of improvement’. However, the global scale may not pick up the various effects of interventions on different symptoms (itching, pain, pain in sex, etc). One trial (Bracco 1993) did not report the degree of improvement; instead, they reported the number of participants who had improvement or remission of symptoms. We, therefore, revised the outcome as ‘participant-rated improvement or remission of symptoms’ and reported effects on various symptoms, respectively, if the trialists provided relevant data.

In the protocol, we planned a time point of outcome measurement at three to six months into therapy. In one trial (Kiss 2001), outcome measurement was made at five weeks into therapy, which was earlier than we had planned to make the measurement, so although the Kiss trial was too short according to our review protocol, we made the decision to include the trial in our review. In this trial, a significant difference in the clinical score of phimosis was detected (Kiss 2001). Therefore, inclusion of the trial conducted shorter than originally planned did not appear to affect the validity of our review (i.e. if this trial had not found a significant therapeutic benefit from mometasone furoate in the short study period, we may have been led to say that this intervention was not effective). However, the fact is that even over the shorter study period it did have a beneficial effect, so inclusion of this trial has not led to a false negative conclusion regarding mometasone furoate.